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1.1 Background and aim of the study 
Vascular barrier dysfunction, i.e. endothelial hyperpermeability and the subsequent 
edema formation, is involved in the initiation or progression of many diseases, such as 
sepsis, atherosclerosis, diabetes or cancer.1 Despite this knowledge, a 
pharmacological treatment that interferes with barrier-regulating systems in endothelial 
cells is still missing. We recently reported that the hawthorn (Crataegus spp.) extract 
WS® 1442 – a well established phytopharmaceutical to treat mild forms of heart  
failure – offers a promising novel approach for protecting against endothelial barrier 
impairment by activating cAMP/Epac1/Rap1- and inhibiting Ca2+/PKC/RhoA-signaling.2  
In the present study, we focus on endothelial Ca2+-signaling phenomena. Based on 
previous experiments of WS® 1442-evoked inhibition of a thrombin-generated increase 
of cytosolic calcium (Ca2+) levels,2 we hypothesized that WS® 1442 preincubation per 
se might elevate Ca2+ baseline levels. This is challenging, since an increase of 
intracellular Ca2+ concentration ([Ca2+]i) followed by a so-called store-operated calcium 
entry (SOCE) usually leads to the induction of hyperpermeability.3  
In addition, Ca2+/PKC/RhoA and cAMP/Epac1/Rap1 pathways were each found to be 
affected by only one distinct phytochemical group of the extract.4 However, individual 
bioactive compounds could not be identified yet. 
Thus, the aims of the present study were to  
1) examine the mechanisms of how WS® 1442 affects [Ca2+]i in the human 
endothelium, and to 
2) identify or at least narrow down the bioactive compounds of WS® 1442 that are 
responsible for the endothelial activity by bioguided fractionation. 
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1.2 Crataegus extract WS® 1442  
WS® 1442 represents an aqueous alcoholic special extract from leaves and flowers of 
predominantly Crataegus monogyna and laevigata. The extract is standardized to a 
content of 17.3-20.1% oligomeric proanthocyanidins (OPCs). The original hawthorn 
plant (Crataegus spp.) belongs to the rose family and grows as shrubs or trees with 
thorny branches all over the Northern hemisphere. In general, hawthorn is one of the 
oldest known medicinal plants in the Western world.5 It is utilized as a herbal remedy to 
treat chronic heart failure worldwide.6 In various European countries, WS® 1442 has 
even become an approved or registered drug for the treatment of congestive heart 
failure according to the New York Heart Association (NYHA) functional class II.  
1.2.1 Phytochemical composition of Crataegus leaves and 
flowers 
Crataegus preparations of leaves and flowers mainly contain two phytochemical 
groups, flavonoids (1.5–2.0%) and OPCs (2.5%).7 Both groups have been identified to 
exert the cardiovascular protective activity of hawthorn.8,9 Apart from those, pentacyclic 
triterpenic acids (ursolic and oleanolic acid), phenol carboxylic acids (chlorogenic and 
caffeic acid), aliphatic alcohols, amines, purines as well as polymeric carbohydrates 
have been isolated from Crataegus extracts to a lesser extent.9,10  
1.2.1.1 Flavonoids 
Flavonoids (lat. flavus = yellow), of which more than 4000 have been identified so far, 
represent a group of ubiquitous secondary plant metabolites belonging to the major 
class of polyphenols. Concerning biosynthesis, shikimic acid serves as a precursor of 
flavonoids. The flavonoid backbone (C6-C3-C6) contains two aromatic rings that are 
linked to each other by a C3 bridge of different oxidation states. According to their 
chemical structure, flavonoids can be categorized into flavans/catechins, 
flavanones/flavanonols, flavones/flavonols, anthocyanidins and chalcones. In each 
case, the flavonoid backbone can be derivatized for instance by O- or C-glycosylation, 
hydroxylation or methylation.10  
Investigating Crataegus leaves and flowers, a series of flavones, flavanones and 
predominantly flavone glycosides (hyperoside, rutin, vitexin) has been detected.6,7 
Interestingly, flavone glycosides are mainly based on apigenin and luteolin whereas 
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quercetin, kaempferol, and 8-methoxykaempferol provide the basic structures of the 
different flavonol glycosides.7 For glycosylation, β-D-glucose, α-L-rhamnose, α-L-4-
acetyl-rhamnose, xylose, arabinose, rutinose, and neohesperidose have been 
identified. Furthermore, apigenin and luteolin based flavones found in Crataegus form 
C- and O-glycosides while flavonols only build O-glycosides.6 Obviously, the flavonoids 
themselves already represent a huge variety of phytochemical compounds in this drug. 
Figure 1  Common flavonoids of Crataegus leaves and flowers 
1.2.1.2 Oligomeric proanthocyanidins (OPCs) 
Besides monomeric flavonoids, plants also synthesize a group of condensed flavanols, 
called oligomeric proanthocyanidins. This name originates from the fact that OPCs can 
be hydrolyzed into colored anthocyanidins upon acidification. Depending on the 
hydroxylation pattern of the monomers, OPCs are subdivided into prodelphinidins, 
propelargonidins and procyanidins. At this, the procyanidins represent the most widely 
spread group of OPCs in plant kingdom.10 
With regard to Crataegus leaves and flowers, procyanidins composed of predominantly 
two to six monomers of the diastereomeric couple epicatechin and catechin were 
found. In particular, the dimers B1, B2 (Figure 2A), B4, B5, trimer C1 (Figure 2B) and 
tetramer D1 have been isolated and identified. However, glycosylated OPCs have not 
been described in Crataegus leaves and flowers to date.7,10 
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A      B 
Figure 2 Chemical structure of procyanidin B2 (A) and C1 (B). B-group procyanidins contain a  
C-C bond between C4 (upper monomer) and C6 or C8 (lower monomer). Trimeric procyanidins are named 
C-group procyanidins. 
1.2.2 Pharmacology, efficacy and safety of Crataegus 
preparations 
Several well-performed clinical trials11-13 and meta-analyses14 have proven Crataegus 
extracts to be efficacious and safe15 in the treatment of mild heart failure. In a pooled 
study, only baseline severity, but not gender turned out to govern the physiological 
outcomes of WS® 1442 treatment.16 By the aid of animal models as well as in vitro 
experiments, Crataegus extracts were shown to exert positive inotropic,17,18 anti-
arrhythmic19 and cardio-protective activities.20-24 Besides the direct action on the heart, 
Crataegus extracts have been found to influence the vascular endothelium by a NO-
mediated vasorelaxation.25-28 Furthermore, Crataegus extracts were demonstrated to 
impair platelet function,29 lipid metabolism30 and inflammation.31 
1.3 The vascular endothelium 
The vascular endothelium represents a monolayer of closely juxtaposed endothelial 
cells (ECs), which line the inner surface of all blood vessels. These cells are covered 
with a polysaccharide rich layer (glycocalyx) and are attached to a basement 
membrane (basal lamina). The endothelium is no longer considered as an inert 
structure to separate blood and tissues, but displays a dynamic size-selective, semi-
permeable barrier to regulate the flux of fluids and solutes as well as the entry of 
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leukocytes into surrounding tissue.32 Moreover, it is perceived as a multifunctional 
disseminated organ that plays a crucial role in various pathological as well as 
physiological processes, such as regulation of vascular tone, transport of nutrients, 
blood flow homeostasis, host defence, or angiogenesis.33  
1.3.1 Regulation of endothelial permeability 
Vascular permeability in general describes the passage of proteins, fluids and solutes 
across the endothelial barrier.34 Macromolecules cross the endothelial barrier 
transcellularly in a caveolae-mediated vesicular way, whereas molecules less than  
3 nm in diameter diffuse between the adjacent cells in a paracellular manner.35 Under 
physiological conditions, paracellular permeability is limited by interendothelial 
junctions (IEJs) that are comprised of tight junctions and predominantly adherens 
junctions (AJs).34 Vascular endothelial (VE)-cadherin represents the most important 
transmembrane protein forming AJs in ECs. By the aid of catenins, VE-cadherin is 
associated to the cytoskeleton. Hence, a dynamic homeostasis between acto-myosin 
mediated cell contraction and intercellular adhesive forces is crucial to retain 
endothelial barrier function. 
However, this barrier function is altered upon pathological conditions such as 
atherosclerosis, diabetes, inflammation, tumor metastasis or hypertension.36 In most 
cases, endothelial barrier breakdown, i.e. the formation of intercellular gaps,37 is 
caused by the activation of the contractile machinery leading to the formation of stress 
fibers and the subsequent disruption of IEJs followed by degradation or 
internalization.34 Basically, two main signaling pathways regulate paracellular 
endothelial permeability. Figure 3 illustrates these pathways in agreement with the 
models described in literature. 
On the one hand, there is the barrier protecting cyclic adenosine monophosphate 
(cAMP) pathway leading to stabilization of IEJs as well as the cortical actin 
rearrangement. cAMP is able to activate protein kinase A (PKA) which phosphorylates 
vasodilator-stimulated phosphoprotein (VASP) and subsequently leads to the activation 
of the Rho GTPase Rac1.38 Rac1 induces translocation of cortactin to the cell borders 
that promotes the rearrangement of the actin cytoskeleton towards a cortical actin 
ring.37 Furthermore, cAMP activates the exchange protein directly activated by cAMP 
(EPAC1) in a PKA independent manner. EPAC1 functioning as guanine nucleotide 
exchange factor (GEF) activates the Ras-like GTPase Rap1 which results in the 
1  INTRODUCTION 15 
augmentation of VE-cadherin-based cell-cell contacts. 39,40 Additionally, Rap1 is able to 
activate Rac1 by the aid of the two GEFs Tiam1 and Vav2.41  
On the other hand, there is the Ca2+-triggered barrier-disrupting pathway causing stress 
fiber formation and endothelial cell contraction. The Ca2+/calmodulin dependent myosin 
light chain kinase (MLCK) phosphorylates myosin light chain (MLC) thereby enabling 
acto-myosin driven endothelial cell contraction. This contraction can be antagonized by 
myosin light chain phosphatase (MLCP)-evoked dephosphorylation. In addition, Ca2+ 
dependent protein kinase C α (PKCα) activation leads to the formation of actin stress 
fibers in a RhoA dependent manner. Furthermore, the small GTPase RhoA is able to 
inhibit MLCP through its downstream effector Rho kinase (ROCK) which enhances 
MLC phosphorylation.  
Besides this explicit separation of both pathways – cAMP and Ca2+ – certain 
interactions exist. These are indicated in Figure 3 as dotted lines. cAMP-dependent 
PKA is able to prevent MLCK42 as well as RhoA43 activity, thereby protecting 
endothelial barrier function. Then, Rac1 controls RhoA activity.37 Apart from that, PKCα 
can phosphorylate VE-cadherin35 which disrupts junctional integrity. 
Figure 3  Signaling scheme of endothelial barrier function. Solid lines demonstrate signaling 
within one pathway. Dotted lines indicate interactions between the two different signaling pathways. 
Arrows describe activation, dead ends illustrate inhibition. 
For our experiments, we used the biogenic amine histamine and the serine protease 
thrombin to provoke transient endothelial hyperpermeability. Both agents operate via 
Ca2+/PKC/RhoA signaling.32  
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1.3.2 Ca2+-signaling in endothelial cells 
Besides endothelial permeability various endothelial functions depend on changes in 
intracellular Ca2+ concentration ([Ca2+]i). Therefore, calcium ions act as a highly 
versatile second messenger system in the endothelium. One of the most prominent 
examples is the Ca2+/calmodulin dependent activation of endothelial NO synthase 
(eNOS) leading to the production of NO44 and subsequent vasodilation. Apart from that, 
cellular processes such as cell proliferation, angiogenesis or, as previously mentioned, 
endothelial permeability are also regulated by increasing [Ca2+]i.45 Usually, intracellular 
concentrations of free Ca2+ amount to approximately 100 nM, i.e. 20,000 fold lower 
than extracellular concentrations.46 To ensure this Ca2+ gradient across the plasma 
membrane, intracellular Ca2+ is trapped in special Ca2+ stores mainly by means of 
endogenous Ca2+ chelators. In endothelial cells, the endoplasmic reticulum (ER) 
represents the major intracellular Ca2+ store and accounts for 75% of the total 
intracellular Ca2+ reserve. Here, Ca2+ is bound to special Ca2+-binding proteins such as 
calreticulin thereby reaching Ca2+ concentrations of 3 mM within the ER.47 Besides this, 
mitochondria represent another important store of intracellular Ca2+ and account for the 
remaining 25% of the Ca2+ pool.  
Figure 4  Calcium signaling in endothelial cells. Standard black arrows indicate Ca2+ flux across 
membranes. Black bold arrows demonstrate activation, dotted black arrows illustrate tentative interactions 
between Stim-1, Orai and TRPC channels. 
An increase of [Ca2+]i usually displays the initial response of endothelial cells to 
hormonal and chemical transmitters45 or to mechanical stress.48 Similar to other non-
excitable cells, this Ca2+ rise appears in a biphasic manner: Ca2+ release from 
intracellular stores is followed by Ca2+ influx from the extracellular space. Figure 4 
illustrates the fundamental properties and mechanisms of endothelial Ca2+-signaling. 
IP3 R
ER
ATP
ADP
cytosolPlasma 
membrane
NCX
PMCA
ADP
ATP
SERCA
α β γ
GPCR
GDP GTP
PLCβ
ROC
TRPC 3,6,7
PIP2
IP3
DAG
TRPC 1,4
Ca2+ Na+
EF
Stim-1Orai
SOCE
extrusion
1  INTRODUCTION 17 
The most important mechanisms that cause elevated Ca2+ levels in the endothelium 
are moderated by the activation of phospholipase C β (PLCβ) through G-protein 
coupled receptors (GPCR) such as histamine receptor 1 (H1 R) or proteinase-activated 
receptor 1 (PAR1).47,49 PLCβ provokes the formation of inositol-1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG). IP3 generates Ca2+ depletion from the ER through IP3 
receptors (IP3 R), whereas DAG activates Ca2+ influx from the extracellular space via 
canonical transient receptor potential (TRPC) channels TRPC 3, 6, and 7.50,51 
Subsequent to the ER depletion, a Ca2+ influx from the extracellular space typically 
amplifies the elevated cytosolic Ca2+ levels.52 This phenomenon is called store-
operated Ca2+ entry (SOCE). But how is the ER depletion linked to SOCE? Hereby, 
stromal interaction molecule-1 (Stim-1) plays the pivotal role. With an EF-hand domain, 
Stim-1 senses the luminal Ca2+ concentration in the ER.53 Decreasing Ca2+ 
concentrations evoke Stim-1 oligomerization into punctae. Afterwards, Stim-1 
translocates to junctions adjacent to the plasma membrane within the ER. Thereby, it 
can activate proteins of the Orai family which function as pore-forming subunits of 
SOCE channels.54 Additionally, TRPC channels TRPC 1 and 4 seem to be involved in 
SOCE as well. In contrast to the highly selective Orai channels, TRPC channels 
represent non-selective cation channels.52 However, it is not yet entirely clarified, 
whether TRPC channels are associated to Stim-1 and Orai or not.  
To recover Ca2+ baseline levels, endothelial cells can either refill the ER by 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) or export excessive Ca2+ 
to the extracellular space by the plasma membrane Ca2+ ATPase (PMCA) and the 
Na+/Ca2+-exchanger (NCX).55-57 Interestingly, SERCA is also responsible to 
compensate spontaneous Ca2+ leakage out of the ER. 
 2 MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Crataegus extract WS® 1442 
The Crataegus extract WS® 1442 was kindly provided by Dr. Willmar Schwabe GmbH 
& Co. KG (Karlsruhe, Germany). It is a well-defined special dry extract of leaves and 
flowers of mainly Crataegus monogyna and laevigata (4-6.6:1), standardized to a 
content of 17.3-20.1% oligomeric proanthocyanidins. For extraction, ethanol 45% (w/w) 
was utilized. 
The extract was freshly dissolved to a concentration of 100 µg/ml, thereby using 0.1% 
DMSO for complete solubilization. 
2.1.2 Fractions of Crataegus extract WS® 1442 
WS® 1442 was stepwise fractionated using different chromatographic methods as 
indicated in the fractionation scheme (Figure 5). Most of the fractionation was 
performed by Evelyn Hartung within her Master Thesis58 at the Ludwig-Maximilians-
University Munich in collaboration with Dr. Willmar Schwabe GmbH & Co. KG. 
The first fractionation step of WS® 1442 was designated 30 to 36 containing 4 different 
fractions. Subfractions of fraction 32 were numbered 32.1 to 32.10 for example. 
The new fractions were investigated by immunocytochemistry (subfractions 34.x) or 
Ca2+ measurement (subfractions 32.x and the derived subfractions), respectively. Only 
those subfractions showing biological activity in these assays were taken into 
consideration and underwent additional subfractionation steps. 
In a first case, WS® 1442 subfractions were utilized in fixed concentrations of 5 µg/ml 
or 10 µg/ml. Alternatively, subfractions were applied in concentrations related to their 
weight proportion (yield) of the original extract (100% ? 100 µg/ml). 
Similar to WS® 1442, subfractions were also dissolved using 0.1% DMSO just before 
starting the experiment. 
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Figure 5  Fractionation scheme of WS® 1442. WS® 1442 was stepwise fractionated using different 
kinds of chromatography as indicated., insoluble residue. Fractions/subfractions were provided by  
Dr. Willmar Schwabe GmbH & Co. KG. 
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2.1.3 Biochemicals, inhibitors and cell culture reagents 
Table 1  Biochemicals 
Reagent Producer 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
DMSO AppliChem, Darmstadt, Germany 
Histamine Sigma-Aldrich, Taufkirchen, Germany 
Thrombin Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Tween® 20 BDH/Prolabo®, Ismaning, Germany 
 
All other used biochemicals were purchased from Sigma-Aldrich, AppliChem, Carl Roth 
or Merck. 
Table 2  Inhibitors 
Inhibitor Producer 
2-Aminoethyldiphenyl borate (2-APB) Sigma-Aldrich, Taufkirchen, Germany 
Complete® mini EDTA free Roche diagnostics, Penzberg, Germany 
2,5-Di-tert-butylhydroquinone (BHQ) Sigma-Aldrich, Taufkirchen, Germany 
NaF  Merck, Darmstadt, Germany 
Na3VO4  ICN Biomedicals, Aurora, OH, USA 
Ouabain Sigma-Aldrich, Taufkirchen, Germany 
Phenylmethylsulfonyl fluoride (PMSF)  Sigma-Aldrich, Taufkirchen, Germany 
Thapsigargin Santa Cruz, Heidelberg, Germany 
U73122 Sigma-Aldrich, Taufkirchen, Germany 
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Table 3  Cell culture reagents 
Reagent Producer 
Amphotericin B 250 µg/ml AppliChem, Darmstadt, Germany 
Collagen A/G Biochrom AG, Berlin, Germany 
Collagenase A Roche, Mannheim, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
Sigma-Aldrich, Taufkirchen, Germany 
Endothelial Cell Growth Medium (ECGM) 
with Supplement Mix  #C-39215 
PromoCell, Heidelberg, Germany 
FCS gold  PAA Laboratories, Pasching, Austria 
HAT supplement 50x liquid Invitrogen, Karlsruhe, Germany 
M199 medium PAA Laboratories, Pasching, Austria 
MEM amino acids 50x PAA Laboratories, Pasching, Austria 
MEM vitamins 100x PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
2.2 Cell culture 
2.2.1 Buffers, solutions and reagents 
The following buffers, solutions and reagents were used for the isolation as well as for 
the cultivation of endothelial cells: 
Table 4  Cell culture buffers 
PBS (pH 7.4)  PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl  123.3 mM  NaCl 137 mM
Na2HPO4 10.4 mM KCl 2.68 mM
KH2PO4 3.2 mM Na2HPO4 8.10 mM
H2O   KH2PO4 1.47 mM
   MgCl2 0.50 mM
   CaCl2 0.68 mM
   H2O 
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Table 5  Cell culture solutions 
Growth medium HUVEC/HMEC  Stopping medium 
ECGM  500 ml  FCS gold 10%
Supplement Mix #C-39215 23.5 ml M199 
FCS gold 50 ml  
Amphothericin B  
(250 µg/ml) 
5 ml   
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 
5 ml   
 
DMEM  Growth medium EA.hy926 cells 
DMEM  10 g  FCS 9.9%
NaHCO3 0.85 g HAT 0.99%
HEPES 6 g DMEM 
Amphothericin B 
(250 µg/ml) 
5 ml   
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 
10 ml   
H2O ad 1000 ml   
 
Freezing medium  Trypsin/EDTA (T/E) 
FCS gold 50%  Trypsin 0.05%
DMSO 8% EDTA 0.02%
Growth medium PBS 
 
Collagen G  Collagen A 
Collagen G 0.001%  Collagen A 0.01%
PBS PBS 
 
 
FCS gold (fetal calf serum) was used after heat inactivation: FCS gold was partially 
thawed for 30 min at room temperature. Afterwards, it was totally thawed at 37°C and 
finally inactivated at 56°C for 30 min. FCS aliquots were stored at -20°C. 
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2.2.2 Endothelial cells 
Endothelial cells (ECs) were cultured in an incubator (Heraeus, Hanau, Germany) 
ensuring constant humidity at 37°C with 5% CO2. Utilizing the PCR detection kit 
Venor®GeM (Minerva Biolabs, Berlin, Germany), cells were routinely tested for 
mycoplasma contamination. 30 min before use, cell culture flasks, Petri dishes and 
multiwell plates were coated with Collagen G. Glass coverslips were pretreated with 
Collagen A. For EA.hy926 cells, coating was not necessary. 
2.2.2.1 HMEC-1 – human dermal microvascular endothelial cells 
The cell line CDC/EU.HMEC-1 was kindly provided by the Centers for Disease Control 
and Prevention (Atlanta, GA, USA). Transfecting human dermal microvascular 
endothelial cells with a plasmid coding for the transforming SV40 large T-antigen led to 
the formation of the immortalized HMEC-1 cell line. This cell line still maintains 
endothelial morphologic, phenotypic, and functional characteristics.59,60 HMECs were 
solely used for macromolecular permeability assays. 
2.2.2.2 HUVECs – human umbilical vein endothelial cells 
Human umbilical cords were kindly provided by Klinikum München Pasing, Frauenklinik 
München West/Krüsmannklinik, Rotkreuzklinikum München, and Wolfart Klinik 
Gräfelfing. After childbirth, umbilical cords were deposited in PBS+ Ca2+/Mg2+ 
containing penicillin (100 U/ml)/streptomycin (100 μg/ml), and stored at 4°C. Cells were 
freshly isolated every week. The umbilical vein was washed with PBS+ Ca2+/Mg2+, filled 
with 0.1 g/l collagenase A, and incubated for 45 min at 37°C. To attain endothelial cells, 
the vein was flushed with stopping medium and the cell suspension was centrifuged 
(1,000 rpm, 5 min). Subsequently, cells were resuspended in growth medium and 
plated in a 25 cm2 flask (passage #0). After reaching confluency, cells were trypsinized 
and plated in a 75 cm2 flask. Experiments were performed using cells at passage #3.  
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2.2.2.3 EA.hy926 cells 
EA.hy926 cells were kindly provided by C.J.S. Edgell (NC, USA). These cells represent 
one of the most frequently used and best characterized permanent human umbilical 
vein endothelial cell line. They were generated by fusing human umbilical vein 
endothelial cells (HUVECs) with the human lung carcinoma cell line A549 by the aid of 
polyethylene glycol.61 This cell line was shown to still possess typical characteristics of 
the endothelial phenotype and function, like the presence of Weibel-Palade bodies 
containing von Willebrand factor or the upregulation of ICAM-, VCAM- and E-selectin-
expression upon TNFα- treatment.60,62 EA.hy926 cells were employed in passages  
> 65 and cultivated using Dulbecco’s modified Eagle’s medium (DMEM) containing 
HAT (hypoxanthin, aminopterin, thymidine) for hybrid cell selection. EA.hy926 cells 
were exclusively used for calcium measurements. 
2.2.3 Passaging 
Having reached confluency, cells were either sub-cultured 1:3 in 75 cm2 culture flasks 
or plated for experiments in multiwell-plates, dishes or on glass coverslips. For 
passaging, medium was removed and cells were washed twice with PBS. Afterwards, 
cells were incubated with T/E for 1-2 min at 37°C. Thereafter, cells were gradually 
detached and the digestion was terminated using stopping medium. After centrifugation 
(1,000 rpm, 5 min, 20°C), the pellet was resuspended in growth medium and cells were 
finally plated. 
2.2.4 Freezing and thawing 
HUVECs were only used until passage #3 without intermediate freezing/thawing steps. 
For freezing, confluent HMECs out of a 75 cm2 flask were trypsinized, centrifuged 
(1,000 rpm, 5 min, 20°C) and resuspended in 3 ml ice-cold freezing medium. 1.5 ml 
aliquots were frozen in cryovials. After storage at -80°C for 24 h, aliquots were 
transferred into liquid nitrogen for long-term storage. To thaw cells, a cryovial was 
warmed to 37°C and the content was immediately mixed with prewarmed growth 
medium. In order to remove remaining DMSO, cells were centrifuged, resuspended in 
growth medium and cultured in a 75 cm2 culture flask. 
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2.3 Cell viability assays 
2.3.1 CellTiter-Blue® Cell Viability Assay  
The CellTiter-Blue® Reagent contains the indicator dye resazurin. Viable cells retain 
the ability to reduce this non-fluorescent indicator resazurin into resorufin, which is 
highly fluorescent. The CellTiter-Blue® Cell Viability Assay was performed according to 
the manufacturer’s protocol (Promega Corp., Madison, WI, USA): HUVECs were grown 
to confluency in 96-well plates and treated as indicated. Afterwards, cells were 
incubated for 3 h with the CellTiter-Blue® Reagent and fluorescence (ex: 560 nm,  
em: 590 nm) was measured using a SpectraFluorPlus plate reader (Tecan, Crailsheim, 
Germany). 
2.3.2 Trypan Blue staining 
HUVECs were cultured in 6-well plates and treated as indicated. Supernatant was 
collected and cells were washed twice with PBS. Cells were trypsinized and 
resuspended in M199 containing 10% FCS. Cell suspension and supernatant were 
mixed. Finally, cells were stained with trypan blue (Sigma Aldrich, Taufkirchen, 
Germany) and analyzed using a Vi-CellTM XR cell viability analyzer (Beckman Coulter, 
Fullerton, CA, USA). 
2.3.3 ATP measurement 
The luciferase-catalyzed, ATP dependent oxidation of luciferin causes light emission. 
This property was utilized to determine cellular ATP contents luminometrically. The 
ATP Bioluminescence Assay Kit HS II (Roche Diagnostics GmbH, Mannheim, 
Germany) was performed according to the manufacturer’s protocol: Briefly, HUVECs 
were cultured in 24-well plates and treated as indicated. Cells were incubated for 5 min 
with pre-warmed lysis buffer to detach the adherent cells. Subsequently, cells were 
harvested on ice to prevent ongoing cellular events. Afterwards, HUVECs were boiled 
for cell lysis (2 min, 95°C), centrifuged and supernatants were diluted 1:1 with dilution 
buffer. Samples were analyzed by integrating the luciferase-generated luminescence 
signal over 10 s using an Orion II Microplate Luminometer (Berthold Detection 
Systems, Pforzheim, Germany). 
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2.4 Western Blot analysis 
2.4.1 Sample preparation 
Endothelial cells were treated as indicated, washed once with ice-cold PBS and then 
lysed in modified RIPA lysis buffer for phosphoproteins. Cells were frozen at -80°C. 
Afterwards, cells were scraped off on ice, transferred to Eppendorf tubes (Peske, 
Aindling-Arnhofen, Germany) and centrifuged (14,000 rpm, 10 min, 4°C). An aliquot of 
the supernatant was utilized to determine protein concentration via Bradford assay. 
Remaining supernatant was mixed with Laemmli sample buffer (3x) and samples were 
finally heated at 95°C for 5 min. Samples were kept at -20°C until Western blot 
analysis. 
Table 6  Buffers for protein sample preparation 
Lysis buffer for phosphoproteins  3x Laemmli buffer 
Tris/HCl (pH 7.4) 50 mM  Tris/HCl (pH 6.8) 187.5 mM
NaCl 150 mM SDS (sodium 6%
Nonidet NP 40 1% dodecyl sulfate) 
Deoxycholic acid 0.25%  Glycerol 30%
SDS 0.1%  Bromphenol blue 0.025%
Na3VO4 0.3 mM  H2O 
NaF 1.0 mM  β-Mercaptoethanol 12.5%
β-Glycerophosphate 3.0 mM   
Pyrophosphate 10 mM   
H2O   
Freshly added:   
Complete®mini EDTAfree 4.0 mM   
PMSF 1.0 mM   
H2O2 600 µM   
2.4.2 Protein quantification – Bradford assay 
In order to employ equal amounts of proteins in all samples for Western blot analysis, 
protein concentrations were determined using the Bradford Assay. After measurement, 
protein concentration was adjusted by adding Laemmli sample buffer (1x). 
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Bradford Assay was performed as previously described, thereby using Coomassie 
Brilliant Blue G250 (Carl Roth, Karlsruhe, Germany) to stain proteins.63 10 μl protein 
samples were incubated with 190 μl Bradford solution (Roti®-Quant Bradford Reagent, 
Carl Roth, Karlsruhe, Germany, 1:5 dilution in water) for 5 min upon shaking. 
Thereafter, absorbance was measured photometrically at 592 nm (Tecan Sunrise 
Absorbance reader, TECAN, Crailsheim, Germany). Protein standards were obtained 
by stepwise diluting a 2 mg/ml stock solution of bovine serum albumin (BSA). Linear 
regression was used to determine the actual protein concentration of each sample. 
2.4.3 SDS-Page electrophoresis 
According to Laemmli et al.,64 proteins were separated by discontinuous SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). Equal amounts of protein were 
loaded on discontinuous polyacrylamide gels, which are composed of a separating and 
a stacking gel. Samples were separated using the Mini-PROTEAN 3 electrophoresis 
module (Bio-Rad, Munich, Germany). To ensure optimal separation of the proteins, the 
concentration of acrylamide (RotiphoreseTM Gel 30, Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany) in the separating gel was adapted to their molecular weights. 
Electrophoresis was run at 100 V for 21 min for protein stacking and at 200 V for  
45 min for protein separation. By the aid of a prestained protein ladder (PageRulerTM, 
Fermentas, St. Leon-Rot, Germany), the molecular weight of the proteins was 
determined. 
Table 7  Acrylamide gels and electrophoresis buffer 
Separating gel 10%  Stacking gel 
RotiphoreseTM Gel 30  33.3%  RotiphoreseTM Gel 30  17%
Tris (pH 8.8) 375 mM Tris (pH 6.8) 125 mM
SDS 0.1% SDS 0.1%
TEMED 0.1%  TEMED 0.2%
APS 0.05%  APS 0.1%
H2O  H2O 
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Electrophoresis buffer 
Tris  0.3%
Glycine 1.44%
SDS 0.1%
H2O 
2.4.4 Tank electroblotting 
Subsequent to protein separation, proteins were transferred to a nitrocellulose 
membrane (Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany) by 
electroblotting.65 A blotting sandwich was prepared in a box filled with 1x tank buffer as 
follows: cathode–pad–blotting paper–separating gel (from SDS-PAGE)–nitrocellulose 
membrane–blotting paper–pad–anode. The membrane was equilibrated with 1x tank 
buffer 15 minutes before starting the tank blot. Sandwiches were mounted on the Mini 
Trans-Blot® system (Bio-Rad, Munich, Germany) and the chamber was filled with ice-
cold 1x tank buffer. Additionally, a cooling pack was inserted to avoid excessive heat. 
Transfers were performed at 4°C, 100 V for 90 min. 
Table 8  Tank blotting buffer 
5x Tank buffer  1x Tank buffer 
Tris base 240 mM  5x Tank buffer 20%
Glycine 195 mM Methanol 20%
H2O  H2O 
2.4.5 Protein detection 
Prior to the immunological detection of the relevant proteins, unspecific protein binding 
sites were blocked. For this purpose, the membrane was incubated for 2 h at room 
temperature in either non-fat dry milk powder 5% (Blotto) or BSA 5%. Afterwards, the 
membrane was incubated with the respective primary antibody at 4°C overnight. 
Subsequent to four washing steps with PBS containing 0.1% Tween® 20 (PBS-T), the 
membrane was incubated with the secondary antibody, followed by four additional 
washing steps. All incubation steps were performed under gentle agitation. For protein 
visualization, two different methods have been used depending on the labels of the 
secondary antibodies: enhanced chemiluminescence or infrared imaging. 
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2.4.5.1 Enhanced chemiluminescence 
Membranes were incubated for 2 h with the HRP-conjugated secondary antibody. In 
order to detect protein bands, luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) was 
used as a substrate. The membrane was incubated with ECL (enhanced 
chemiluminescence) solution for 1 minute (ECL Plus Western Blotting Detection 
Reagent RPN 2132, GE Healthcare, Munich, Germany). Protected from light, the 
membrane was exposed to an X-ray film (Super RX, Fuji, Düsseldorf, Germany), which 
detected the arising luminescence. Subsequently, the film was developed using the 
Curix 60 Developing system (Agfa-Gevaert AG, Cologne, Germany). 
2.4.5.2 Infrared imaging 
A secondary antibody coupled to Alexa Fluor® 680 with emission at 700 nm was used. 
Membranes were incubated for 1 h. The incubation as well as the washing procedure 
were performed protected from light. Protein bands of interest were detected utilizing 
the Odyssey imaging system (Li-COR Biosciences, Lincoln, NE). 
Table 9  Primary antibodies 
Antigen Source Dilution In Provider 
β-actin  mouse monoclon. 1:1,000 Blotto 5% Millipore 
phos.-MLC2T18/S19 rabbit polyclon. 1:1,000 BSA 5% Cell Signaling 
Table 10 Secondary antibodies 
Antibody Dilution In Provider 
Alexa Fluor® 680 goat anti-mouse IgG 1:20,000 Blotto 1% Molecular Probes 
Goat anti-rabbit HRP 1:10,000 Blotto 1% Dianova 
2.4.5.3 Quantification 
The intensity of Western blot bands detected with enhanced chemiluminescence was 
quantified using the ImageJ Gel analyzer (Version 1.43q; NIH, Bethesda, MD, USA).  
Analysis of bands obtained from infrared imaging was performed with the Quant Data 
function of the Odyssey software (Odyssey 2.1, Infrared Imaging system, Li-COR 
Biosciences, Lincoln, NE). 
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2.5 Macromolecular permeability assay 
HMECs were grown to confluency on collagen G-coated 12-well Transwell® inserts 
(pore size 0.4 μm; Corning, New York, NY, USA). At t = 0 min, fluorescein 
isothiocyanate (FITC)-dextran (40 kDa; 1 mg/ml; Sigma-Aldrich, Taufkirchen, 
Germany) was added to the upper compartment of the Transwell® plates and cells 
were treated as indicated. Out of the lower compartment, samples were taken at  
t = 0/5/10/15/30/60 min. To analyze the fluorescence increase of the samples  
(ex: 485 nm, em: 535 nm), a SpectraFluorPlus plate reader (Tecan, Crailsheim, 
Germany) was used. Mean fluorescence of samples from untreated cells at t = 60 min 
was defined as 1.0. Data are expressed as percent increase of fluorescence versus 
control. 
Figure 6  Scheme of a Transwell® insert with a HMEC monolayer 
2.6 Immunocytochemistry and confocal laser scanning 
microscopy 
A Zeiss LSM 510 META confocal microscope (40x oil objective, Zeiss, Oberkochen, 
Germany) was used to obtain immunofluorescence images of fixed cells. 
HUVECs were grown to confluency in 8-well μ-slides (ibiTreat, ibidi GmbH, 
Martinsried, Germany). Cells were treated as indicated, washed with warm PBS+ 
Ca2+/Mg2+ and fixed with 10% Accustain® paraformaldehyde (Sigma-Aldrich, 
Taufkirchen, Germany) at room temperature for 10 min. After three washing steps with 
PBS, HUVECs were permeabilized for 2 min with 0.2% Triton X-100. Again, cells were 
washed three times and subsequently incubated for 20 min with 0.2% BSA to block 
unspecific binding. Thereafter, cells were incubated over night with the primary 
antibodies in 0.2% BSA at 4°C. Following three washing steps with PBS, cells were 
incubated for 1 h at room temperature with the respective AlexaFluor®-labeled 
secondary antibodies or rhodamine-phalloidin for F-actin staining in 0.2% BSA. Finally, 
preparations were again washed three times with PBS, embedded in FluorSaveTM 
upper compartment
HMECs
Transwell® insert
FITC-dextran 40 kD
microporous membrane
lower compartment
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Reagent mounting medium (Merck, Darmstadt, Germany) and covered with 8 mm x  
8 mm glass coverslips (custom made by Helmut Saur Laborbedarf, Reutlingen, 
Germany). Slides were stored at 4°C protected from light. 
Table 11  Primary antibodies 
Antigen Source Dilution In Provider 
phos.-cortactinY421 rabbit polyclon. 1:400 BSA 0.2% Cell Signaling 
VE-cadherin mouse monoclon. 1:400 BSA 0.2% Santa Cruz 
Table 12  Secondary antibodies 
Antibody/dye Dilution In Provider 
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) 
1:400 BSA 0.2% Molecular Probes 
Alexa Fluor® 633 goat anti-mouse IgG 
(H+L) 
1:400 BSA 0.2% Molecular Probes 
rhodamine-phalloidin 1:400 BSA 0.2% Molecular Probes 
2.7 Patch clamp recordings 
The patch clamp recordings were kindly performed by Dr. Oleksandr Bondarenko in the 
lab of Prof. Graier (Institute for Molecular Biology and Biochemistry, Medical University 
Graz, Austria). 
HUVECs were grown on glass coverslips. Membrane potential was recorded by patch-
clamp technique in a current-clamp mode using a List EPC7 amplifier (List, Germany). 
Borosilicate glass pipettes were pulled with a Narishige puller (Narishige Co. Ltd, 
Tokyo, Japan), fire-polished and had a resistance of 4–5 MΩ. The signals obtained 
were digitized with a sample rate of 10 Hz utilizing a Digidata 1200A A/D converter 
(Axon Instruments, Foster City, CA, USA). Data collection and analysis were performed 
with the Clampex and Clampfit software of pClamp (version 8.2, Axon Instruments). 
Figures show representative traces of a single cell measurement obtained from one 
adjacent cell out of a cell cluster. For K+-free measurements, the standard external 
solution was adapted to 150 mM NaCl to compensate the absence of KCl whereas all 
the other constituents remained unchanged. 
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Table 13  Buffers for patch-clamp measurements 
Standard external solution  
(ph 7.4/NaOH) 
 Solution filled in patch pipette 
(ph 7.2/KOH) 
NaCl 145 mM  Potassium aspartate  100 mM
KCl 5 mM KCl 40 mM
MgCl2 1.2 mM HEPES 10 mM
HEPES 10 mM  MgCl2 1 mM
Glucose 10 mM  EGTA 0.2 mM
CaCl2 2.4 mM  H2O 
H2O   
2.8 Calcium imaging 
To analyze cellular calcium responses, two different methods were used:  
Fura-2 calcium imaging and FRET-based calcium measurements. 
Table 14  Frequently used agonists/antagonists of endothelial Ca2+-signaling 
Agonist/antagonist  
2-APB66 IP3 R antagonist 
BHQ67 Reversible SERCA antagonist 
Histamine68 H1 R agonist 
Thapsigargin67 Irreversible SERCA antagonist 
Thrombin69 PAR1 agonist 
U7312270 PLC antagonist 
Table 15  Buffers for Ca2+ measurements 
Ca2+-containing HEPES buffer  
(pH 7.4/NaOH) 
 Ca2+-free HEPES buffer  
(pH 7.4/NaOH) 
CaCl2 2 mM  NaCl 138 mM
NaCl 138 mM  MgCl2 1 mM
MgCl2 1 mM KCl 5 mM
KCl 5 mM HEPES 10 mM
HEPES 10 mM  EGTA 1 mM
Glucose 10 mM  Glucose 10 mM
H2O  H2O 
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Ca2+-containing 0 Na+ HEPES buffer 
(pH 7.4/KOH) 
 Ca2+-free 0 Na+ HEPES buffer  
(pH 7.4/KOH) 
CaCl2 2 mM  Choline chloride 138 mM
Choline chloride 138 mM  MgCl2 1 mM
MgCl2 1 mM KCl 5 mM
KCl 5 mM HEPES 10 mM
HEPES 10 mM  EGTA 1 mM
Glucose 10 mM  Glucose 10 mM
H2O  H2O 
 
EA.hy926-loading buffer 
(pH 7.35/NaOH) 
CaCl2 2 mM
Choline chloride 135 mM
MgCl2 1 mM
KCl 5 mM
HEPES 10 mM
NaHCO3 2.6 mM
KH2PO4 0.44 mM
Na2HPO4 0.34 mM
MEM amino acids 50x 2%
MEM vitamins 100x 1%
Glucose 10 mM
L-Glutamine 2 mM
Penicillin/Streptomycin 1%
Amphotericin B 1%
H2O 
2.8.1 Fura-2 measurements 
Changes of cytosolic calcium concentrations were detected ratiometrically using the 
fluorescent dye Fura-2.71 Upon calcium binding, the excitation maximum of Fura-2 is 
shifted from 380 nm to 340 nm, whereas the emission wavelength remains unchanged 
(510 nm). The emission ratio of 340/380 is directly correlated to the amount of cytosolic 
calcium. For measurements, a membrane-permeable derivative called Fura-2-
acetoxymethyl ester (Fura-2-AM) was applied. Having crossed the cell membrane, 
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Fura-2-AM is cleaved through cellular esterases resulting in the generation of Fura-2, 
which is consequently trapped in the cell. 
A static tempered and a perfusion system were used for Fura-2 measurements.  
2.8.1.1 Perfusion system 
The author performed all EA.hy926 cell calcium measurements at Prof. Graier’s lab 
(Institute for Molecular Biology and Biochemistry at Medical University Graz, Austria). 
Graier’s experimental setup of the perfusion system was adopted and successfully 
established at Prof. Vollmar’s lab by the author. Thereafter, HUVEC measurements 
were carried out in Munich.  
All experiments were performed at room temperature (20-23°C). HUVECs were 
cultured on glass coverslips (Ø 42 mm, Helmut Saur Laborbedarf, Reutlingen, 
Germany), loaded for 45 min in the dark with 4 μM Fura-2-AM (Biotrend, Cologne, 
Germany) in HEPES-buffered solution and washed twice. For further procedures the 
coverslips were mounted into an experimental chamber and perfused (1 ml/min, 
ismatec MS-reglo peristaltic pump/2 stop tubing Tygon R3607 ID 2.06 mm, IDEX 
Health & Science GmbH, Glattbrugg, Germany) with the appropriate HEPES-buffered 
solution. Fluorescence measurements (ex: 340/380 nm, em: 510 nm) were obtained by 
a Zeiss Axiovert 200 inverted microscope (40x objective) with a Polychrome  
V monochromator and an IMAGO-QE camera (TILL Photonics). Images were acquired 
every 3 s and analyzed with the TILLvisION Software 4.0.1.2 (TILL Photonics). Each 
data point of the graph was calculated from nine randomly chosen cells out of a 
uniform confluent cell monolayer. F340/F380 values of these nine cells are expressed as 
mean  S.E.M. One representative plot of each graph is shown for clarity. At least three 
independent experiments (with not less than three replicates per treatment) using 
different HUVEC preparations were performed. 
In case of EA.hy926 cell measurements, 6 glass coverslips (Ø 30 mm, Paul Marienfeld 
GmbH & Co.KG, Lauda Königshofen, Germany) were loaded simultaneously for 45 min 
in the dark with 4 μM Fura-2-AM in EA.hy926-loading buffer. Cells were washed twice 
and kept in loading buffer at room temperature protected from light until measurement. 
The perfusion rate amounted to 2 ml/min. For data acquisition, a Zeiss Axiovert 200 M 
(40x oil objective, Zeiss) microscope, a polychromator illumination system (VisiChrome 
High Speed, Xenon lamp, Visitron Systems, Puchheim, Germany) and a 
thermoelectric-cooled CCD camera (Photometrics Coolsnap HQ, Visitron Systems) 
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were utilized. Data recordings and analysis were achieved by VisiView 2.0.6 (Universal 
Imaging, Visitron Systems, Puchheim, Germany). Experiments were performed once 
with at least three replicates per treatment. 
2.8.1.2 Static tempered system  
Experiments were performed at 37°C. HUVECs were grown to confluency on ibidi  
8-well µ-slides (ibiTreat, ibidi GmbH) and incubated for 30 min with 2 μM Fura-2-AM in 
HEPES buffer, washed twice, and treated as indicated. Fluorescence measurements 
were obtained using an incubator in addition to the identical technical equipment as 
described above. For each sample, a total period of 30 min with images being acquired 
every 5 s was analyzed with the TILLvisION Software 4.0.1.2 (TILL Photonics). Each 
data point of the different graphs was calculated from a randomly chosen rectangle 
containing at least 20 adjacent cells, of which mean values are expressed. One 
representative plot of each graph is shown for clarity. At least three independent 
experiments (with at least two replicates per treatment) using different HUVEC 
preparations were performed. 
2.8.2 FRET analysis using D1ER 
All FRET analyses were performed by the author in Prof. Graier’s lab. 
In this study, we took advantage of fluorescence resonance energy transfer (FRET) to 
detect alterations in the free Ca2+ concentration of the endoplasmic reticulum (ER) 
using the D1ER cameleon.72-74 The D1ER plasmid contains a mutant calmodulin 
(CaM)/skeletal muscle myosin light chain kinase (skMLCK) pair that is cloned between 
ECFP (donor) and citrine (acceptor). Moreover, a calreticulin signal sequence and a 
KDEL (lysine, aspartic acid, glutamic acid, leucine) ER-retention tag are inserted to 
facilitate an effective and specific localization of the construct inside the ER. Upon 
Ca2+-binding, CaM wraps around M13 (CaM binding peptide of skMLCK) leading to a 
conformational change of the construct which in turn allows FRET.  
For measuring FRET, cells were excited at 420 nm (ECFP) and the emitting 
fluorescence of ECFP (480 nm) as well as citrine (535 nm) were recorded to calculate 
the emission ratio of both wavelengths. This ratio is correlated to the free [Ca2+]ER. 
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2.8.2.1 Cell transfection 
For transfection experiments, cDNA for D1ER was inserted into a pcDNA3 vector 
(Invitrogen, Karlsruhe, Germany). HUVECs and EA.hy926 cells were plated on glass 
coverslips (Ø 30 mm, cultured in 6-well plates) to approximately 80% confluency and 
transiently transfected with the plasmid DNA using the TransFastTM (Promega, Vienna, 
Austria) transfection reagent. For this purpose, 1.5 µg DNA per each 6-well were 
diluted in 1 ml transfection medium (HUVEC: M199, EA.hy926: DMEM without 
Pen/Strep, AmB), mixed with 4 µl TransFastTM reagent and incubated for 15 min at 
room temperature. Meanwhile, cells were washed once with transfection medium to 
exclude remaining FCS and antibiotics. Then, medium was removed and cells were 
incubated for 1 h with 1 ml of the transfection mixture at 37°C. Thereafter, 1 ml of pre-
warmed culture medium was added per well. 4-5 h later, this medium mixture was 
aspirated and replaced by 2 ml of culture medium. Experiments were performed 48 h 
(EA.hy926 cells: 24 h) after transfection.  
2.8.2.2 FRET measurements 
Transfected cells were washed twice, transferred into the experimental chamber, 
perfused (2 ml/min) with HEPES-buffered solution and treated as indicated. 
Images were obtained by using a Zeiss Axiovert 200 M (40x oil objective, Zeiss) 
microscope, a polychromator illumination system (VisiChrome High Speed, Xenon 
lamp, Visitron Systems, Puchheim, Germany) and a thermoelectric-cooled CCD 
camera (Photometrics Coolsnap HQ, Visitron Systems). D1ER-expressing cells were 
excited at 420 nm (high speed monochromator, Visitron Systems) and emission was 
recorded at 480 and 535 nm. Emission filters were adjusted through a filter-wheel 
(MAC 6000, Ludl Electronic Products, Hawthorne, NY, USA). Devices were controlled 
and data were recorded by VisiView 2.0.6 (Universal Imaging, Visitron Systems, 
Puchheim, Germany). To compensate the signal decay in the F535/F480 ratio during 
the experiments, which was probably due to photobleaching or photochromism of 
D1ER, the changes of the ER Ca2+ concentration were expressed as (F535/F480)/R0. 
Cells were analyzed individually. The graph represents the result of one single cell 
measurement. Each run was repeated several times within the same experiment.  
Three independent experiments using different HUVEC preparations were performed. 
For EA.hy926 cells, experiments were performed once with at least three replicates per 
treatment. 
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2.9 Statistical analysis 
Bar graph data are standardized to control measurements and expressed as mean  
 S.E.M. Each experiment was at least performed three times. In case of HUVECs, a 
different preparation (i.e. cells from a different donor) was utilized each time. The 
precise number of independently performed experiments is noted in the respective 
figure legend. Statistical analysis was performed using the GraphPad Prism software 
version 5.04 (GraphPad Software, San Diego, CA, USA). To compare only two 
different groups, a paired t-test was performed. For analyzing three or more groups, a 
one-way analysis of variance (ANOVA) followed by a Newman-Keuls post-test was 
carried out. Statistical significance was assumed if p  0.05.  
 3 RESULTS 
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3.1 Mechanisms of WS® 1442-induced Ca2+-signaling in 
endothelial cells 
Our group previously demonstrated that WS® 1442 preincubation prevents thrombin-
induced Ca2+ response in HUVECs.2 In the present study, we hypothesized that  
WS® 1442 preincubation per se elevates calcium baseline levels. Therefore, the first 
aim of this study was to explore the mechanisms of how WS® 1442 affects [Ca2+]i in the 
human endothelium. 
3.1.1 WS® 1442 elevates cytosolic Ca2+ levels in human 
endothelial cells 
We investigated the basic impact of WS® 1442 on cytosolic Ca2+ levels in HUVECs 
(Figure 7). After a lag time of 5 min, WS® 1442 clearly augmented [Ca2+]i, which finally 
reached a plateau value after 30 min of treatment. In contrast to untreated cells, which 
show the typical Ca2+ response caused by the hyperpermeability-inducing factor 
histamine, WS® 1442 treatment abrogated the histamine-evoked Ca2+ signal.  
Figure 7  WS® 1442 increases [Ca2+]i and prohibits a histamine-evoked Ca2+ response. The 
change of [Ca2+]i was monitored using Fura-2-AM-loaded HUVECs in a perfusion system. Cells were 
treated for 30 min with WS® 1442 (100 µg/ml, grey line) in HEPES buffer or were left untreated (black line). 
At the end, histamine (100 µM) was added.  
To clarify the reversibility of this observed phenomenon, cells were pretreated with 
WS® 1442 for 24 h (Figure 8, grey line). However, even after this pretreatment, freshly 
added WS® 1442 was still able to induce the same calcium response. Again, histamine 
could not change the elevated Ca2+ signal. Also base levels did not show any 
difference, pointing towards a reversible effect.  
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Figure 8  WS® 1442 reversibly increases [Ca2+]i. The change of [Ca2+]i was monitored using Fura-2-
AM-loaded HUVECs in a perfusion system. Cells were pretreated with WS® 1442 (100 µg/ml) for 24 h  
(24 h pretreated) or left untreated (not pretreated). Afterwards, cells were treated with WS® 1442 (30 min,  
100 µg/ml) in HEPES buffer or left untreated. At the end, histamine (100 µM) was added.  
 
Importantly, the rise of [Ca2+]i was concentration-dependently starting at the lowest 
effective concentration of 20 µg/ml and reaching saturation between 80-100 µg/ml  
(Figure 9). Therefore, WS® 1442 was applied at 100 µg/ml for all further experiments. 
Interestingly, also the onset of the Ca2+ signal was affected: higher concentrations led 
to an earlier onset. 
Figure 9  WS® 1442 causes a concentration-dependent increase of [Ca2+]i. The change of [Ca2+]i 
was monitored using Fura-2-AM-loaded HUVECs in a perfusion system. Cells were perfused with different 
concentrations (10-100 µg/ml) of WS® 1442 in a Ca2+-containing buffer (n = 3). 
Hence, we conclude that WS® 1442 concentration-dependently increases [Ca2+]i and 
inhibits an additional histamine-induced Ca2+ response. 
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3.1.2 WS® 1442 does neither influence endothelial barrier 
function nor endothelial cell contraction 
A rise of [Ca2+]i can trigger actomyosin mediated cell contraction leading to an increase 
of endothelial permeability.75 To check whether WS® 1442 alters basal permeability, 
macromolecular permeability assays were performed. However, WS® 1442 did not 
affect endothelial barrier function (Figure 10) in contrast to the typical [Ca2+]i-increasing 
agents thrombin and thapsigargin (irreversible SERCA inhibitor), which clearly induced 
hyperpermeability.76,77  
A B 
Figure 10  WS® 1442 does not induce endothelial hyperpermeability. A macromolecular 
permeability assay was performed. HMECs were treated with either WS® 1442 (100 µg/ml), thrombin  
(3 U/ml), thapsigargin (1 µM) or were left untreated. (A) One representative image illustrating the time 
course is shown. (B) Data are expressed as mean  S.E.M. at t = 60 min. *, p  0.05 vs. control (n = 5). 
 
WS® 1442 did also not influence endothelial cell contraction (i.e. contractile machinery), 
as indicated by Western blot analysis of the phosphorylation (Thr18/Ser19) status of 
myosin light chain 2 (MLC2). Thrombin and thapsigargin clearly increased MLC 
activation. 
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Figure 11  WS® 1442 does not increase the amount of phosphorylated myosin light chain (MLC). 
The phosphorylation status of MLC was investigated by Western blot analysis using a phospho-T18/S19-
MLC2 antibody. HUVECs were treated for 30 min with thrombin (1 U/ml), thapsigargin (1 µM), WS® 1442 
(100 µg/ml) or were left untreated. (A) One representative Western blot is shown. (B) Data are expressed 
as mean  S.E.M (n = 3). 
 
Thus, WS® 1442 does not influence basal endothelial barrier function or endothelial cell 
contraction, which is in striking contrast to typical [Ca2+]i-elevating agents. 
3.1.3 Cell viability is not affected by WS® 1442 
A rise of [Ca2+]i could be a result of cellular stress induced by WS® 1442.78,79 To clarify 
if HUVECs were stressed upon WS® 1442 application, we studied various hallmarks of 
cell vitality, such as ATP content, cell membrane integrity and cellular metabolic 
activity. The endothelial ATP content did not change upon WS® 1442 (100 µg/ml) 
exposition within 15-60 min (Figure 12A). Moreover, even after long-term treatment  
(24 h) WS® 1442 (1-100 µg/ml) did not alter the percentage of cells with an intact 
plasma membrane (trypan blue dye exclusion, Figure 12B). At this, the detergent  
Triton X-100 served as a positive control. In addition, the metabolic activity of HUVECs 
was also not influenced by WS® 1442 (1-100 µg/ml) after 24 h (CellTiter-Blue® assay, 
Figure 12C).  
 
These results demonstrate that WS® 1442 does not impair endothelial cell vitality. 
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Figure 12  WS® 1442 does not impair cell viability. (A) WS® 1442 does not modify the cellular ATP 
content. Cells were treated with WS® 1442 (100 µg/ml) for 15, 30 or 60 min. Control cells were left 
untreated. ATP contents were determined. Data are expressed as mean  S.E.M. *, p  0.05 (n = 3).  
(B) WS® 1442 does not alter the proportion of intact cells. For 24 h, cells were either treated with different 
concentrations of WS® 1442 (1, 10, 100 µg/ml) or left untreated and a trypan blue staining was performed. 
The positive control was incubated with Triton X-100 (0.2%) just before staining. Data are expressed as 
mean  S.E.M. *, p  0.05 (n = 3). (C) The metabolic activity of HUVECs is not changed due to WS® 1442 
treatment. Cells were treated with different concentrations of WS® 1442 (1-100 µg/ml) for 24 h and the 
CellTiter-Blue® assay was performed. Fluorescence intensity of the reduced dye, which correlates to the 
number of viable cells, was determined. Data are expressed as mean  S.E.M. *, p  0.05 (n = 3). 
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3.1.4 WS® 1442 does not interfere with the endothelial  
Na+/K+-ATPase 
WS® 1442 was reported to interfere with the Ca2+ response in cardiomyocytes by 
blocking the Na+/K+-ATPase similar to the mode of action of cardiac glycosides.18 
Information about an influence of WS® 1442 on endothelial Na+/K+-ATPase is not 
available. Using patch clamp technique, we investigated whether WS® 1442 affects the 
resting membrane potential of ECs, which is mainly controlled by this ATPase. As 
mentioned under 2.7, all patch clamp measurements were performed by Dr. Oleksandr 
Bondarenko. WS® 1442 transiently depolarized ECs by approx. 4 mV (Figure 13A). In 
comparison, the cardiac glycoside ouabain, used at a concentration sufficient to block 
both α1 and α2 ion-transporting subunits of the Na+/K+-ATPase,80 depolarized the cells 
by approx. 10 mV (Figure 13A). Additional administration of WS® 1442 on an already 
ouabain-depolarized membrane potential had no further influence (Figure 13B).  
A B 
Figure 13  WS® 1442 differently affects endothelial membrane potential compared to ouabain. 
The membrane potential of HUVECs was recorded using patch clamp technique. (A) WS® 1442 only 
slightly depolarizes membrane potential in contrast to ouabain. HUVECs were treated with WS® 1442  
(100 µg/ml) for 430 s. After washing out, ouabain (100 µM) was applied (n = 5). (B) WS® 1442 does not 
alter an already ouabain-depolarized membrane potential. 1 min after starting the run, HUVECs were 
treated with ouabain (100 µM). 3 min later, WS® 1442 (100 µg/ml) was added. At the end, both agents 
were washed out (n = 6). 
 
Employing a K+ deprivation/readdition protocol (Figure 14), removal of extracellular K+, 
i.e. inhibition of the ATPase, caused a strong endothelial cell depolarization by approx.  
11 mV. Accordingly, K+ readdition, which reestablished the functionality of the ATPase, 
repolarized the cell membrane. WS® 1442 did only marginally affect this repolarization 
process.  
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Figure 14  WS® 1442 does not inhibit Na+/K+-ATPase in HUVECs. The membrane potential of 
HUVECs was recorded using patch clamp technique. Cells were perfused with K+-free buffered solution for 
approximately 2 min. After K+ readdition (2 min), external K+ was removed again. 2 min later, cells were 
treated with WS® 1442 (100 µg/ml). After 1.5 min, external K+ was added whilst WS® 1442 treatment 
remained (n = 5). 
 
Finally, we tested whether inhibition of the Na+/K+-ATPase by ouabain affects [Ca2+]i in 
the endothelium. As shown in Figure 15, ouabain – irrespective of the used 
concentration – did not alter [Ca2+]i.  
Figure 15 Ouabain does not affect [Ca2+]i in HUVECs. The change of [Ca2+]i was monitored using 
Fura-2-AM-loaded HUVECs in a tempered static system. 1 min after starting the measurement, ouabain 
(10 or 100 µM) was added. Control cells were left untreated (10 µM: n = 3, 100 µM: n = 2). 
 
Therefore, our data suggest that WS® 1442 does not evoke the profound increase of 
[Ca2+]i by targeting the endothelial Na+/K+-ATPase. 
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3.1.5 WS® 1442 increases [Ca2+]i by emptying the ER with two 
different mechanisms involved 
Under nominally Ca2+-free conditions, WS® 1442 was still able to raise [Ca2+]i  
(Figure 16, black line), suggesting that the increase of [Ca2+]i is generated by 
intracellular calcium stores. The ER represents the main intracellular Ca2+ store. We 
depleted the ER by a combination of the IP3-generating agonist histamine and the 
SERCA pump inhibitor BHQ. Then, histamine was removed and WS® 1442 was added, 
whilst BHQ was permanently present to prevent ER refilling. Upon store depletion,  
WS® 1442 was no longer able to affect cytosolic Ca2+ levels (Figure 16, grey line).  
Figure 16  Having depleted the ER by the combination of histamine/BHQ, WS® 1442 is no longer 
able to increase [Ca2+]i. The change of [Ca2+]i was monitored using Fura-2-AM-loaded HUVECs in a 
perfusion system. Cells were treated with a combination of histamine (100 µg/ml)/BHQ (15 µM) in EGTA-
containing (thus Ca2+-free) buffer. After removing only histamine, WS® 1442 (100 µg/ml) was added. 
Control cells (black line) were only treated with WS® 1442 (100 µg/ml) (n = 4). 
 
Single cell Ca2+-imaging FRET experiments were carried out in D1ER-expressing 
endothelial cells to verify the involvement of the ER. In a Ca2+-containing environment, 
WS® 1442 clearly depleted the ER (Figure 17, grey line). Removal of calcium during a 
continuing WS® 1442 perfusion did not alter the signal. This behavior was similar to 
that of BHQ-treated cells, which served as control (Figure 17, black line). Interestingly, 
after removing WS® 1442 and switching to a Ca2+-containing buffer, an ER refilling 
could not be observed, pointing towards an irreversible SERCA inhibition (at least 
during observation). In contrast, ER refilling immediately started when the reversible 
SERCA inhibitor BHQ was eliminated.  
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Figure 17  WS® 1442 depletes the ER and prohibits its refilling. [Ca2+]ER was measured using FRET 
technique. D1ER transfected HUVECs were treated with either WS® 1442 (100 µg/ml, grey line) or BHQ 
(15 µM, black line) in Ca2+-containing buffer. After 9.5 min, Ca2+ was removed by switching into EGTA-
containing buffer. Approx. 4.5 min later, BHQ or WS® 1442 was removed and Ca2+ was added (n = 3). 
 
Besides SERCA inhibition, the ER is well known to be depleted in endothelial cells by 
activating the IP3 receptor, too.47 Thus, we applied two different inhibitors of the IP3 
pathway: 2-APB (Figure 18A), an antagonist of the IP3 receptor, and U73122  
(Figure 18C), which blocks the formation of IP3 by phospholipase C (PLC) inhibition. If 
endothelial cells were preincubated with these inhibitors in a Ca2+-free buffer, the  
WS® 1442-triggered increase of [Ca2+]i was either reduced (Figure 18A, grey line) or 
decelerated (Figure 18C, grey line) compared to control measurements (black lines). 
Functionality of these inhibitors was proven by confirming their inhibitory action on a 
[Ca2+]i increase evoked by histamine (Figure 18B/D).  
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Figure 18  Pharmacological interaction with the IP3 pathway alters the WS® 1442-evoked rise of 
[Ca2+]i. The change of [Ca2+]i was monitored using Fura-2-AM-loaded HUVECs in a perfusion system. 
Cells were pretreated with either 2-APB (A, 100 µM, 15 min, grey line) or U73122 (C, 1 µM, 10 min, grey 
line) in EGTA-containing buffer or were left untreated (black line). Subsequently, WS® 1442 (100 µg/ml) 
was added (n = 3). (B, D) Functionality of each inhibitor is demonstrated using histamine (100 µM). 
 
We conclude that WS® 1442 increases [Ca2+]i by a dual mechanism: It blocks SERCA 
and activates the IP3 pathway. 
3.1.6 WS® 1442 inhibits store-operated Ca2+ entry and Ca2+ 
extrusion capacity 
After a lag time of approx. 5 min, WS® 1442 clearly increased [Ca2+]i in a Ca2+-
containing as well as in a Ca2+-free (EGTA) buffer (Figure 19). The plateau values, the 
onset of the Ca2+ signal, and the areas under the curve were identical for the different 
buffers. This confirms that the WS® 1442-evoked rise of [Ca2+]i does not depend on the 
extracellular [Ca2+].  
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Figure 19  WS® 1442 induces a Ca2+ response that is independent of the extracellular [Ca2+]. The 
change of [Ca2+]i was monitored using Fura-2-AM-loaded HUVECs in a perfusion system. HUVECs were 
treated with WS® 1442 (100 µg/ml) for 21 min in Ca2+-containing (black line) or Ca2+-free (grey line) buffer 
(n = 3). (A) One representative graph is shown. (B) Area under the curve was calculated taking into 
account all single graphs of Ca2+-containing and Ca2+-free measurements out of 3 independent 
experiments. The averaged area under the ratiometric signal was normalized to 100% for the Ca2+-
containing results. Data are expressed as mean  S.E.M. *, p  0.05 (n = 3). 
 
In contrast, histamine-treated cell recordings highlight the strong difference between 
Ca2+-containing and Ca2+-free measurements: In the Ca2+-free buffer, the lack of SOCE 
prevented the development of an elevated plateau phase (Figure 20A). This effect 
could be mimicked by pretreating endothelial cells for 24 h with WS® 1442: Applying 
histamine to these pretreated cells in a Ca2+-containing buffer did no longer cause the 
typical [Ca2+]i plateau, suggesting an irreversible SOCE inhibition (Figure 20B).  
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Figure 20  Histamine application on WS® 1442-pretreated cells in HEPES buffered solution 
imitates a Ca2+-free measurement. The change of [Ca2+]i was monitored using Fura-2-AM-loaded 
HUVECs in a perfusion system. (A) Histamine induces a Ca2+ response, which depends on the 
extracellular [Ca2+]. HUVECs were treated with histamine (100 µM) for 21 min in Ca2+-containing (black 
line) or Ca2+-free (grey line) buffer, respectively (n = 3). (B) WS® 1442 blocks store-operated calcium entry 
in an irreversible manner. Cells were pretreated for 24 h with WS® 1442 (100 µg/ml) or only with vehicle 
(not pretreated). 1 min after starting the measurement, cells were perfused with histamine (100 µM)-
containing buffer (n = 4). 
 
Furthermore, we found that the addition of extracellular Ca2+ does not alter the 
increased [Ca2+]i levels upon application of WS® 1442 in a Ca2+-free buffer (Figure 21, 
red line). This is in obvious contrast to BHQ-treated cells, which exhibited a clear 
SOCE due to the readdition of extracellular Ca2+ (Figure 21, black line). Combining 
both treatments by preincubating HUVECs with the SERCA inhibitor BHQ in a Ca2+-
free buffer before adding WS® 1442 also prevented SOCE after Ca2+ readdition  
(Figure 21, grey line).  
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Figure 21  WS® 1442 prohibits BHQ-induced SOCE. The change of [Ca2+]i was monitored using 
Fura-2-AM-loaded HUVECs in a perfusion system. In EGTA-containing buffer, HUVECs were treated with 
either BHQ (15 µM, black line), WS® 1442 (100 µg/ml, red line) or a combination of both (grey line), 
thereby preincubating the cells for 8.5 min with BHQ. At the end, external Ca2+ was added by switching to 
normal buffer (n = 3). 
Besides the influence of WS® 1442 on Ca2+ influx, we investigated if the Ca2+ efflux is 
affected as well. We observed that WS® 1442-induced increase of [Ca2+]i clearly 
remained at an elevated level even after extracellular Ca2+ had been removed  
(Figure 22, grey line). This is in striking contrast to histamine: Ca2+ removal clearly 
lowered [Ca2+]i down to basal levels (Figure 22, black line).  
Figure 22  WS® 1442 prohibits the Ca2+ extrusion of HUVECs. The change of [Ca2+]i was monitored 
using Fura-2-AM-loaded HUVECs in a perfusion system. Cells were treated with either histamine  
(100 µM, black line) or WS® 1442 (100 µg/ml, grey line) in HEPES buffer. 16.5 min later, extracellular Ca2+ 
was removed by changing the buffer solution to an EGTA-containing buffer (n = 3). 
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Thus, WS® 1442 prevents the wash out of augmented Ca2+ levels in ECs, which 
explains why the signal remains at an elevated range in the plateau phase even in 
Ca2+-free measurements. Obviously, Ca2+ is trapped within the cell at least in the time 
frame of our experiment, i.e. for more than 10 min. Nevertheless, after 24 h we 
routinely observed normal baseline [Ca2+]i levels even in a Ca2+-containing buffer as 
shown in Figure 8 and Figure 20B.  
These results suggest that WS® 1442 inhibits Ca2+ extrusion capacity and - despite its 
ER-depleting action - does not induce SOCE. Moreover, WS® 1442 even irreversibly 
prevents agonist-induced SOCE. 
3.1.7 WS® 1442 induced Ca2+-signaling in EA.hy926 cells 
Further research in this project will depend on the successful transfection of plasmids 
or siRNA into endothelial cells, which strongly limits the usage of primary HUVECs. 
EA.hy926 cells – easily to be transfected – represent a very well established cell line to 
investigate endothelial Ca2+-signaling. Several selected key experiments were 
performed in EA.hy926 cells to check their response to WS® 1442 treatment.  
3.1.7.1 WS® 1442 increases cytosolic Ca2+ levels and inhibits Ca2+ extrusion 
capacity in EA.hy926 cells 
WS® 1442 immediately increased [Ca2+]i in a peak-plateau shaped manner  
(Figure 23A). Moreover, we detected that the WS® 1442-induced rise of [Ca2+]i clearly 
remained on elevated levels when extracellular Ca2+ had been removed. Even if the 
extract had been excluded, Ca2+ levels still persisted in the elevated status. We further 
investigated this phenomenon. We applied WS® 1442 during the very strong histamine-
induced plateau phase which prevented Ca2+ extrusion after removal of external Ca2+ 
(Figure 23B, grey line) in contrast to control measurements (Figure 23B, black line). In 
a Na+-free environment, the Na+/Ca2+-exchanger is deactivated and consequently, Ca2+ 
extrusion can only be generated by the plasma membrane Ca2+ ATPase (PMCA). 
Figure 23C clearly illustrates that Ca2+ extrusion was strongly inhibited in Na+-free 
buffer. 
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Figure 23  WS® 1442 influences [Ca2+]i in EA.hy926 cells. The change of [Ca2+]i was monitored 
using Fura-2-AM-loaded EA.hy926 cells in a perfusion system. (A) WS® 1442 immediately increases 
[Ca2+]i in EA.hy926 cells. Cells were treated with WS® 1442 (100 µg/ml) in HEPES buffer. 5 min later, 
external buffer was changed into an EGTA-containing buffer. After 4 min, the extract was removed (n = 1).  
(B) WS® 1442 inhibits Ca2+ extrusion capacity. Cells were treated with histamine (100 µM) in HEPES 
buffer. After 5 min, WS® 1442 (100 µg/ml) was added and 6 min later, external Ca2+ was removed. Control 
cells (black line) were only treated with histamine (100 µM) (n = 1). (C) WS® 1442 alters Ca2+ extrusion 
mainly by blocking PMCA. Cells were treated with a combination of histamine (100 µM)/BHQ (15 µM) in 
Na+-free HEPES buffer. 2 min later, WS® 1442 (100 µg/ml) was added. After 7 min, external Ca2+ was 
removed and 5.5 min later, Na+ was added. At the end, only pure HEPES buffer was perfused. Control 
cells (black line) were only treated with histamine (100 µM)/BHQ (15 µM) (n = 1). 
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Thus, WS® 1442 increases [Ca2+]i and in addition alters Ca2+ extrusion capacity mainly 
by blocking PMCA in EA.hy926 cells.  
3.1.7.2 WS® 1442 raises [Ca2+]i by depleting the ER 
WS® 1442 was still able to raise [Ca2+]i in EGTA-containing buffer, pointing towards an 
involvement of intracellular calcium stores (Figure 24A, black line). In Figure 24A (grey 
line) we used BHQ to deplete the ER. Subsequent to this ER depletion, WS® 1442 was 
no longer able to affect cytosolic Ca2+ levels. To verify these data FRET experiments of 
D1ER-expressing EA.hy926 cells were performed (Figure 24B). In EGTA-containing 
buffer, WS® 1442 clearly depleted the ER. Calcium readdition during a continuing  
WS® 1442 perfusion did not alter the signal. Even after removing WS® 1442, an ER 
refilling could not be observed, suggesting an irreversible SERCA inhibition (at least 
within our observation period).  
A      B 
Figure 24  WS® 1442 depletes intracellular stores. (A) Having depleted the ER upon BHQ treatment, 
WS® 1442 is no longer able to increase [Ca2+]i. The change of [Ca2+]i was monitored using Fura-2-AM-
loaded EA.hy926 cells in a perfusion system. Cells were treated with BHQ (15 µM) in EGTA-containing 
buffer. 9 min later, WS® 1442 (100 µg/ml) was added. Control cells (black line) were only treated with  
WS® 1442 (100 µg/ml) (n = 1). (B) WS® 1442 depletes the ER. [Ca2+]ER was measured using FRET 
technique. D1ER transfected EA.hy926 cells were treated with WS® 1442 (100 µg/ml) in EGTA-containing 
buffer. After 5 min, Ca2+ was added by switching into Ca2+-containing buffer. 4 min later, WS® 1442 was 
removed (n = 1). 
 
As a result, WS® 1442 increases [Ca2+]i due to an ER depletion. Moreover, this 
depletion is at least partly caused by an irreversible SERCA inhibition.   
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3.2 In search of the bioactive compounds of WS® 1442  
The original extract had been fractionated into four different fractions using column 
chromatography. By the aid of these fractions, we recently could show that the two 
different endothelial signaling mechanisms triggered by the extract can clearly be 
assigned to specific phytochemical groups of WS® 1442.4 
Table 16  First fractionation of WS® 1442 
Fraction Eluate % (m/m) of WS® 1442 Main compounds 
30 H2O 56.83 Non-phenolic, aliphatic 
compounds 
32 Ethanol 95% 17.00 Flavonoids 
34 Methanol 100% 12.17 Oligomeric 
proanthocyanidins 
36 Acetone 70% 8.13 Proanthocyanidins n > 4 
 
The most prominent activation of the barrier protecting cAMP/Rap1/Rac1 pathway 
could be detected using fraction 34 (oligomeric proanthocyanidins, OPCs). Concerning 
the inhibition of the barrier disrupting Ca2+/PKC/RhoA signaling, fraction 32 (small 
phenolic compounds, flavonoids) showed the strongest effect. However, both fractions 
still represent multi-component systems. For a better understanding of this complex 
polypharmacology, it would be important to identify the active principles of WS® 1442.  
Consequently, the second part of this study aimed to elucidate the bioactive 
compounds of this multi-component phytopharmaceutical. Therefore, fractions 32 and 
34, representing the active fractions of WS® 1442 in the endothelium, were stepwise 
subfractionated as indicated in the Materials and Methods part and examined for their 
endothelial activity.  
3.2.1 Subfractions 32.x differently inhibit agonist-induced Ca2+-
signaling 
Fura-2-AM Ca2+ measurements were performed to determine which subfraction of 
fraction 32 still exhibits an inhibitory effect on agonist-induced Ca2+-signaling. For all 
experiments, thrombin was employed to activate the Ca2+-signaling cascade. In the 
following paragraph, only the active subfractions are visualized for clarity. 
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3.2.1.1 Subfractions 32.x 
According to their weight proportion, subfractions were applied in concentrations 
related to 100 µg/ml of the original extract. Only two out of ten subfractions, i.e. 
subfractions 32.1 and 32.4, could prevent the typical thrombin-induced biphasic Ca2+ 
response (Figure 25A, B). As described above for WS® 1442, both subfractions also 
had raised [Ca2+]i during the preceding incubation period (Figure 25C, D).  
A      B 
C      D 
Figure 25  Only subfractions 32.1 and 32.4 affect endothelial Ca2+-signaling. The change of [Ca2+]i 
was monitored using Fura-2-AM loaded HUVECs in a tempered static system. (A, B) Subfractions 32.1 
and 32.4 inhibit thrombin-induced Ca2+ response in HUVECs. Cells were either preincubated for 30 min 
with fraction 32.1 (A: 4.32 µg/ml), fraction 32.4 (B: 3.83 µg/ml) or left untreated. At t = 1 min, thrombin  
(1 U/ml) was added (n = 3). (C, D) Subfractions 32.1 and 32.4 raise [Ca2+]i in HUVECs. HUVECs were 
either treated with subfraction 32.1 (C, 4.32 µg/ml), subfraction 32.4 (D, 3.83 µg/ml) or just vehicle at  
t = 1 min (n = 3). 
 
Hence, subfractions 32.1 and 32.4, which represent the major part of fraction 32, were 
further fractionated (Figure 29) and analyzed. 
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3.2.1.2 Subfractions 32.1_x 
Among subfractions 32.1_x, only subfractions 32.1_5 and 32.1_6 seemed to affect 
cytosolic calcium levels in concentrations related to their weight proportion. However, 
thrombin was still able to evoke its Ca2+ response (Figure 26A, C). As a result of 
repeated fractionation, the applied concentrations of the subfractions were already very 
low. Taking into account the loss of starting material during fractionation, we verified 
our results enhancing the concentrations to 5 µg/ml of each subfraction. Once again, 
subfractions 32.1_5 and 32.1_6 altered cytosolic calcium levels (Figure 26B, D). This 
time, they even inhibited the Ca2+ signal caused by thrombin and exhibited clearly 
elevated baseline levels.  
A      B 
C      D 
Figure 26  Only subfractions 32.1_5 and 32.1_6 affect endothelial Ca2+-signaling. The change of 
[Ca2+]i was monitored using Fura-2-AM loaded HUVECs in a tempered static system. (A, B) Cells were 
either preincubated for 30 min with subfraction 32.1_5 (A: 0.07 µg/ml, B: 5 µg/ml), subfraction 32.1_6  
(C: 0.17 µg/ml, D: 5 µg/ml) or left untreated. At t = 1 min, thrombin (1 U/ml) was added (n = 1).  
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Interestingly, besides the two subfractions mentioned above, subfraction 32.1_uR 
turned out to influence endothelial Ca2+-signaling as well (Figure 27). Thrombin was no 
longer able to induce SOCE – indicated through the lack of the elevated plateau phase 
– after preincubating HUVECs with subfraction 32.1_uR.  
Figure 27  Subfraction 32.1_uR inhibits thrombin induced SOCE in HUVECs. The change of [Ca2+]i 
was monitored using Fura-2-AM loaded HUVECs in a tempered static system. Cells were either 
preincubated for 30 min with subfraction 32.1_uR (5 µg/ml) or left untreated. At t = 1 min, thrombin  
(1 U/ml) was added (n = 3). 
 
As a result, subfractions 32.1_5 and 32.1_6 were further fractionated (Figure 29). 
3.2.1.3 Subfractions 32.4_x 
Regarding subfractions 32.4_x, we achieved similar results compared to subfractions 
32.1_x. Again, the last two subfractions – subfraction 32.4_4 and 32.4_5 – influenced 
[Ca2+]i and inhibited thrombin-evoked Ca2+ response (Figure 28A, C). Once more, we 
reassessed our results by applying both subfractions with 5 µg/ml (Figure 28B, D): Both 
subfractions completely inhibited the Ca2+ signal caused by thrombin.  
A      B 
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C      D 
Figure 28  Only subfractions 32.4_4 and 32.4_5 affect endothelial Ca2+-signaling. The change of 
[Ca2+]i was monitored using Fura-2-AM loaded HUVECs in a tempered static system. (A, B) Cells were 
either preincubated for 30 min with subfraction 32.4_4 (A: 0.1 µg/ml, B: 5 µg/ml), subfraction 32.4_5  
(C: 0.05 µg/ml, D: 5 µg/ml) or left untreated. At t = 1 min, thrombin (1 U/ml) was added (n = 1). 
 
Hence, subfractions 32.4_4 and 32.4_5 were further fractionated.  
Interestingly, additional data acquired by Simone Fuchs indicate that subfraction 
32.4_uR applied with 5 µg/ml affects SOCE similar to subfraction 32.1_uR.  
At the end, the purification process led to the identification of three distinct flavonoids, 
namely rutin, hyperoside and isoquercitrin. However, these flavonoids did not exhibit 
any Ca2+-signaling activity (Simone Fuchs). Consequently, other flavonoids/compounds 
that could not be identified so far, are expected to play the decisive role in Ca2+-
signaling. 
Figure 29 summarizes the action profiles of subfractions 32.x as well as their 
fractionation scheme. According to this fractionation scheme, subfractions 32.1_x and 
32.4_x were separated using the same chromatographic setup. Surprisingly, the 
sequence of the active subfractions is similar in both fractionation branches, suggesting 
that corresponding subfractions might contain comparable compounds.  
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Figure 29  Fractionation scheme of fraction 32. Ca2+-active fractions are marked by colored boxes 
(blue: highly active, light blue: slightly active)., insoluble residue. 
 
3.2.1.4 Ca2+-active subfractions of WS® 1442 neither impair endothelial barrier 
integrity nor contractile machinery 
As already mentioned above, an increase of [Ca2+]i can activate the contractile 
machinery of endothelial cells which in turn induces hyperpermeability. Thus, we 
examined if the Ca2+-active subfractions alter basal endothelial barrier integrity  
(Figure 30). In this setting, the cAMP pathway activating fraction 34 was utilized as 
negative control. Once again, only the typical [Ca2+]i-increasing agents thrombin and 
thapsigargin clearly evoked hyperpermeability. 
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A 
B 
Figure 30  None of the selected fractions/subfractions of WS® 1442 induces endothelial 
hyperpermeability. A macromolecular permeability assay was performed. HMECs were treated with 
either WS® 1442 (100 µg/ml), thrombin (3 U/ml), thapsigargin (1 µM), fraction 32 (17 µg/ml), fraction 34  
(12 µg/ml), subfraction 32.1 (4.32 µg/ml), subfraction 32.4 (3.82 µg/ml), or were left untreated. (A) One 
representative image illustrating the time course is shown. (B) Data are expressed as mean  S.E.M. at  
t = 60 min. *, p  0.05 vs. control (left panel: n = 4, right panel: n = 5). 
 
As indicated by Western blot analysis of the phosphorylation (Thr18/Ser19) status of 
myosin light chain 2 (MLC2), the contractile machinery was not influenced by the Ca2+-
active subfractions which is in agreement with WS® 1442 treatment (Figure 31). By 
contrast, thrombin and thapsigargin clearly activated MLC. 
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A 
B 
Figure 31  Ca2+-active fractions/subfractions of WS® 1442 do not increase the amount of 
phosphorylated myosin light chain (MLC). The phosphorylation status of MLC was investigated by 
Western blot analysis using a phospho-T18/S19-MLC2 antibody. HUVECs were treated for 30 min with 
thrombin (1 U/ml), thapsigargin (1 µM), WS® 1442 (100 µg/ml), fraction 32 (17 µg/ml), subfraction 32.1 
(4.32 µg/ml), subfraction 32.4 (3.83 µg/ml) or were left untreated. (A) One representative Western blot is 
shown. (B) Data are expressed as mean  S.E.M. *, p  0.05 (n = 3). 
 
To conclude, Ca2+-active fractions/subfractions behave similar to the original extract. 
They do neither induce hyperpermeability nor activate endothelial cell contraction, 
which is in striking contrast to the well established Ca2+-increasing agents thrombin or 
thapsigargin.  
3.2.2 Subfractions 34.x differently affect cAMP pathway 
In order to analyze cAMP pathway activation by the respective subfractions, we 
focused on cortactin, a downstream effector of cAMP/Rac1 signaling.81,82 Upon 
phosphorylation on Tyr421, cortactin gets activated and mediates cortical actin 
rearrangement which tightens the endothelial barrier. Using confocal laser scanning 
microscopy, we investigated the phosphorylation status of cortactin triggered by the 
different subfractions of fraction 34. Original fraction 34 was used as positive control. 
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All subfractions apart from fraction 34.2 induced phosphorylation of cortactin and 
subsequent cortical actin formation in a concentration of 10 µg/ml (Figure 32A). To 
distinguish between the biological activity of the different subfractions, experiments 
were repeated utilizing a lower concentration of 5 µg/ml (Figure 32B). Only subfractions 
34.3 and 34.5 were still able to evoke cortactin phosphorylation and actin 
rearrangement. 
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Figure 32  Subfractions 34.x differently affect cortactin and subsequently the actin cytoskeleton. 
Images were achieved by confocal microscopy after immunocytochemical staining. A confluent HUVEC 
monolayer was either left untreated, treated with fraction 34 (A: 30 µg/ml, B: 12 µg/ml) or with one of the 
different subfractions of fraction 34 (34.1-34.6, A: 10 µg/ml, B: 5 µg/ml) for 15 min. One representative 
image is shown for each type of treatment (n = 3). White bar: 50 µm.  
 
To summarize, subfractions 34.3 and 34.5 exhibited the strongest activation of the 
cAMP pathway amongst all subfractions and thus were chosen to be further 
fractionated and analyzed (Figure 33).  
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This project has been pursued by Simone Fuchs. However, the available column 
chromatographical system Sephadex LH-20 was unable to properly separate these 
subfractions probably due to molecular rearrangements.83 For this reason, two typical 
oligomeric proanthocyandins – procyanidin B2 and C1 – that had been isolated from 
the original extract by Dr. Willmar Schwabe GmbH & Co. KG in a different attempt were 
applied. Indeed, it could be demonstrated that at least these two OPCs account for the  
WS® 1442-evoked activation of the cAMP pathway in human endothelial cells. 
Figure 33  Fractionation scheme of fraction 34. cAMP-active subfractions are marked by colored 
boxes (orange: highly active, light orange: slightly active). 
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4.1 WS® 1442 protects endothelial barrier integrity 
despite increasing [Ca2+]i 
As yet, only two compounds have been described that reduce endothelial permeability 
despite increasing [Ca2+]i: ATP84 and sphingosine 1-phosphate (S1-P),85 the 
prototypical endogenous barrier-protecting agent. Our study for the first time shows 
that this action can also be evoked by a phytopharmaceutical, WS® 1442. S1-P was 
shown to induce Rac activation due to the rise of [Ca2+]i. Rac, in turn, ameliorated 
intercellular adhesion, thereby stabilizing endothelial barrier integrity. Our group had 
previously checked this potential connection between increased [Ca2+]i and Rac 
activation in WS® 1442-treated ECs.4 However, a link does not exist in our model 
system. 
4.1.1 Key role of SOCE in endothelial hyperpermeability  
Instead of Ca2+-triggered Rac activation, we propose another mode of action: Typically, 
an agonist-induced depletion of the ER – no matter if it is IP3- or SERCA-mediated – 
causes the induction of a Stim-1-triggered SOCE from the extracellular space.52,86 
Proteins of the Orai family function as pore-forming subunits of SOCE channels 
responsible for the so-called calcium release activated calcium current (ICRAC). It is still 
a controversial matter if TRP channels connected to store-operated calcium currents 
(ISOC) are also involved in Stim-1/Orai-gated regulation of SOCE or not.87-89 The 
presence of SOCE, accompanied by an interendothelial gap formation due to EC 
shape changes, is crucial for the induction of endothelial hyperpermeability.50,90 This 
phenomenon has been demonstrated in endothelial cells from various vascular  
beds.91-93 Mechanistically, a further study impressively showed that in bovine artery 
ECs the activation of SOCE is coupled to the phosphorylation of MLC leading to the 
formation of intercellular gaps and increased permeability. Both thrombin and 
thapsigargin activated a Ca2+ entry and led to the phosphorylation of MLC, which could 
be prevented by blocking Ca2+ influx. Concerning thapsigargin, an inhibition of SOCE 
also prevented the induction of hyperpermeability.94 
In our study, we could confirm that these two agonists raise [Ca2+]i, cause MLC 
phosphorylation and increase permeability also in HUVECs. Surprisingly, although 
increasing [Ca2+]i, WS® 1442 did not cause these effects. We assume that this might be 
due to its inhibition of SOCE. Moreover, WS® 1442 did not trigger intercellular gap 
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formation. By contrast, WS® 1442 caused a substantial cortical F-actin distribution by 
activating the Epac1/Rap1/Rac1/cortactin pathway.2 
4.1.2 Suggested modes of SOCE inhibition induced by  
WS® 1442 
Interestingly, it has been described that the cytoskeleton plays a pivotal role in the 
modulation of SOCE.95-97 Galan et al.97 demonstrated that stabilization of the cortical 
actin ring by the actin polymerizing agent jasplakinolide leads to the inhibition of 
thapsigargin-induced association of Stim-1 with SOC channels. This in turn prevents 
SOCE in HEK-293 cells. The authors assume that actin filaments as well as 
microtubules function as a cortical barrier which impedes the association between 
Stim-1 and the Ca2+ channels and consequently prohibits SOCE. Therefore, stabilizing 
these networks serves to prevent SOCE. As demonstrated in Figure 21, WS® 1442 is 
able to inhibit SOCE in a low Ca2+ environment after Stim-1 clustering has already 
been activated upon BHQ treatment. This indicates that WS® 1442 most likely impairs 
Stim-1/SOC channel communication. Thus, a possible mechanism for WS® 1442-
evoked SOCE inhibition might be the strong rearrangement of cortical actin upon  
WS® 1442 treatment.2 
Additionally, a negative feedback mechanism of Stim-1 regulation could supplement 
WS® 1442-induced SOCE inhibition. By the aid of an EF-hand domain, Stim-1 senses 
the Ca2+ concentration within the lumen of the ER.53 Upon ER depletion, Stim-1 
oligomerizes into punctae and translocates within the ER to junctions adjacent to the 
plasma membrane. Thereby, it can activate Orai.54 Malli et al.98 could demonstrate that 
an elevated cytosolic Ca2+ concentration is able to inhibit subplasmalemmal Stim-1 
clustering, preventing SOCE and consequently cellular Ca2+ overload. Obviously, 
SOCE is under the control of cytosolic free Ca2+. This mechanism is crucial to maintain 
endothelial barrier integrity, since cytosolic Ca2+ overload is believed to evoke F-actin 
disintegration leading towards endothelial hyperpermeability.99 Our preliminary results 
in EA.hy926 cells suggest that WS® 1442 treatment does not induce Stim-1 clustering 
in contrast to histamine addition. A possible explanation would be that the interplay 
between WS® 1442-induced increase of [Ca2+]i and inhibition of Ca2+ extrusion might 
transiently generate a situation of high Ca2+ which prevents Stim-1 clustering.  
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According to the fact that WS® 1442 actually blocks agonist-induced SOCE in a low 
Ca2+ situation, we believe that actin rearrangement by activating cAMP/Epac1/Rap1 
pathway2 contributes in a superior way to WS® 1442-evoked SOCE inhibition 
compared to the negative regulation of Stim-1 clustering. Moreover, one might even 
speculate that this SOCE inhibition combined with the ER depletion enables WS® 1442 
to overcome thrombin-induced deleterious effects on endothelial barrier. This will be an 
interesting topic of further research.  
4.2 WS® 1442 and its influence on Ca2+ extrusion 
capacity 
Concerning the endothelial Ca2+ extrusion capacity, the question arises of how  
WS® 1442 is able to hamper the decrease of elevated Ca2+ levels. WS® 1442 inhibits 
the SERCA pump, which prevents Ca2+ reuptake into the ER. As a result, increased 
Ca2+ levels can only be eliminated through a plasma membranous transport.100 In 
principle, this can mainly be achieved by the plasma membrane Ca2+ ATPase (PMCA), 
by the Na+/Ca2+-exchanger (NCX) or by both,55-57 depending on the cell type or tissue. 
Originally, it has been believed that the predominant role of NCX is to counteract large 
and rapid raises of [Ca2+]i in contrast to PMCA, which regulates the basal status. In calf 
pulmonary artery endothelial cells, it was shown that PMCA acts as a high-affinity Ca2+ 
removal system to correct baseline levels, whereas the low-affinity NCX erases fast 
and large increases of Ca2+.101 However, this hypothesis was refuted due to the strong 
functional versatility among the different isoforms of PMCA, of which some also allow a 
rapid Ca2+ clearance.102 PMCA belongs to the P-type ATPases, just as the SERCA 
pump, thereby sharing fundamental properties like membrane topology and reaction 
mechanism. The two pumps, however, display significant sequence differences leading 
to an altered regulation, action of some inhibitors, and role in cellular processes.103 
According to that, BHQ and thapsigargin specifically act on the SERCA pump.104 Based 
on the inhibitory effect of WS® 1442 on SERCA function, we therefore cannot simply 
conclude that PMCA is blocked as well. However, in EA.hy926 cells we got first hints 
that Ca2+ extrusion is in fact considerably abolished by WS® 1442-induced PMCA 
inhibition. Further investigations are needed to clarify the role of PMCA and NCX in the 
WS® 1442-evoked repression of Ca2+ extrusion in our system. 
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4.3 Na+/K+-ATPase and WS® 1442 
In cardiomyocytes, a different target of WS® 1442 was found that is responsible for a 
rise of [Ca2+]i: WS® 1442 increases [Ca2+]i by inhibiting Na+/K+-ATPase similar to the 
mode of action of cardiac glycosides. The extract concentration-dependently displaces 
the cardiac glycoside ouabain from its binding partner, the Na+/K+-ATPase, thereby 
enhancing the force of contraction in human failing and non-failing myocardium.18 In 
addition to its action on the heart, the Na+/K+-ATPase also plays an important role in 
pathological processes of the vasculature.105 Although the regulation of Ca2+ levels 
differs between non-excitable (e.g. endothelial) cells and excitable cardiomyocytes, it 
has nevertheless been reported that ouabain is able to alter [Ca2+]i in the rat 
descending vasa recta106 by targeting the Na+/K+-ATPase and subsequent inhibition of 
the Na+/Ca2+-exchanger. Interestingly, ECs were in fact found to express different 
isoforms of this ATPase107 and ouabain, applied in the nanomolar range, was even 
shown to induce a breakdown of endothelial barrier integrity in ECs, which could be 
overcome by preventing Na+/K+-ATPase blockade using a special digoxin antibody.108 
Referring to Ca2+ measurements and patch clamp recordings, our work clearly shows 
that in the endothelium this ATPase is not the primary target of WS® 1442. 
4.4 Comparison between HUVECs and EA.hy926 cells 
concerning WS® 1442-induced Ca2+-signaling 
For in vitro experiments, immortalized cell lines like EA.hy926 are often chosen 
because of significant advantages such as stable cell viability, unaltered expression 
profile of endothelial cell markers during passaging and genetical homogeneity. In our 
case, EA.hy926 cells would offer the possibility to easier perform transfection 
experiments. It has been described that despite hybridization, EA.hy926 cells still 
maintain endothelial cell characteristics of native HUVECs.62 Nevertheless, we checked 
the comparability between HUVECs and EA.hy926 cells concerning WS® 1442-induced 
Ca2+-signaling. 
This study shows that WS® 1442-induced Ca2+ response does not exclusively appear 
in HUVECs but also in EA.hy926 cells. However, there is a difference regarding the 
onset and the shape of the Ca2+ response: In EA.hy926 cells, WS® 1442 immediately 
elevates [Ca2+]i in a peak-plateau shaped manner, whereas in HUVECs, a lag time of 
approximately 5 min is observed while the peak is completely missing. Because of the 
4  DISCUSSION AND CONCLUSIONS 73 
immediate onset of the Ca2+ signal in EA.hy926 cells, an IP3 involvement besides 
SERCA inhibition can be assumed. This would be in agreement with the dual 
mechanism demonstrated for HUVECs, but has yet to be examined. WS® 1442 
treatment inhibits Ca2+ efflux in both cell types. However, focusing on the histamine-
induced Ca2+ response, EA.hy926 cells exhibit a stronger Ca2+ influx, i.e. SOCE, which 
is indicated throughout the more pronounced plateau phase. Therefore, WS® 1442-
induced SOCE inhibition should be revised in EA.hy926 cells as well.  
To conclude, WS® 1442 treatment seems to influence similar Ca2+-signaling pathways 
in both cell types. Apparent kinetic differences might originate from the epithelial 
portion of the hybrid cell line and, thus, from an altered expression pattern of Ca2+ 
channels. 
4.5 Bioactive compounds of WS® 1442 
The cardiovascular protective activity of hawthorn is ascribed to its flavonoid and 
oligomeric proanthocyanidin8 (OPC) content.9 Consequently, most of the studies 
dealing with the efficacy of hawthorn were accomplished utilizing one of the two 
standardized extracts LI 132 (MCM Klosterfrau Vertriebsgesellschaft mbH) or  
WS® 1442. LI 132 and WS® 1442 are adjusted to a definite content of flavonoids  
(2.2%, LI 132) or OPCs (18.75%, WS® 1442), respectively.  
These polyphenols exert various bioactive properties109,110 such as antioxidant,111-113 
anti-inflammatory114-116 and vasodilatory28,117,118 actions. Interestingly, we could 
demonstrate that these two phytochemical groups also contribute to the observed 
endothelial activity in our study. In fact, we could even assign each group to one single 
pathway regulating endothelial barrier function.4  
4.5.1 Flavonoids and their role in Ca2+-signaling 
Within all fractions, only the flavonoid containing fraction 32 as well as particular 
subfractions 32.x were able to prevent thrombin-induced increase of [Ca2+]i and to 
concomitantly raise [Ca2+]i by themselves. This observation suggests an involvement of 
flavonoids in the WS® 1442-evoked Ca2+ response, even if the three already identified 
flavonoids were not the active candidates.  
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Several groups have already established a clear alliance between flavonoids and 
cellular Ca2+-signaling. For instance, flavonoids impair IgE-mediated proinflammatory 
mediator release119 or Ca2+ dependent cell oxidation120 by inhibiting agonist-evoked 
increase of [Ca2+]i. Therefore, some flavonoids could provide health benefits in the 
treatment of allergic or inflammatory diseases. Additionally, flavonoids themselves are 
able to increase [Ca2+]i by affecting SERCA,121 which could also be observed in  
WS® 1442 treated cells. Certain flavonoids alter ATP affinity to SERCA by binding to 
the cytosolic region of the Ca2+ ATPase between ATP-binding and phosphorylation 
domain. Moreover, they can stabilize the enzyme in one single conformational state 
(E1). As a result, both mechanisms suppress functionality of the pump.67 Interestingly, 
polyhydroxylation of flavones with hydroxylation at position 3 and 6 were shown to be 
particularly relevant for the inhibitory activity.122 In the same study, one of our isolated 
flavonoids, i.e. rutin, was shown to not measurably inhibit SERCA, which is in 
agreement to our findings. In contrast to SERCA inhibition, the antioxidant flavonoids 
were also shown to even safeguard SERCA activity against oxidative damage,123 
whereby the ability to protect the functionality of the Ca2+ ATPase depends on the 
mode of oxidative injury.124  
Besides SERCA, flavonoids also interact with other Ca2+ ATPases, like the Ca2+ 
transport ATPase of synaptosomal vesicles125 or the liver plasma membrane Ca2+ 
pump.126 However, a repression of plasma membrane Ca2+ ATPase (PMCA) 
functionality, which is probably responsible for the altered Ca2+ extrusion capacity upon 
WS® 1442 treatment, has not been described for flavonoids so far. 
Another aspect of flavonoid/Ca2+-signaling interaction concerns myosin light chain 
kinase (MLCK). An agonist-induced increase of [Ca2+]i can activate Ca2+/calmodulin 
regulated MLCK, which subsequently phosphorylates MLC leading towards cell 
contraction.127 As already discussed above, WS® 1442 treatment does not cause MLC 
phosphorylation despite the clear rise of cytosolic Ca2+ levels. Additionally, WS® 1442 
as well as the flavonoid-rich fraction 32 even block thrombin-evoked MLC 
phosphorylation.4 Interestingly, flavonoids were found to inhibit MLCK activity 
demonstrated in vitro on isolated, purified MLCK from chicken gizzard in a kinase 
assay.127 This topic has not been studied in great detail until today, but could be an 
additional explanation for the influence of WS® 1442 on MLC-signaling.  
We conclude that particular flavonoids of WS® 1442 probably inhibit SERCA function. 
Nevertheless, it is still an open question whether these flavonoids are also responsible 
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for the WS® 1442-evoked change of Ca2+ extrusion (NCX, PMCA) and IP3-mediated 
ER depletion or not. It remains to be clarified if unidentified Ca2+-active compounds 
other than flavonoids exist which can complement the WS® 1442-induced Ca2+ 
response.  
4.5.2 Oligomeric proanthocyanidins and endothelial barrier 
function 
We could demonstrate that the OPC rich fraction 34 of WS® 1442,4 its subfractions 
34.3 and 34.5 as well as the pure procyanidins B2 and C1 activate the barrier 
protecting and strengthening cAMP-signaling most significantly within all WS® 1442 
fractions.  
Several publications report a barrier protecting property of OPCs. With the aid of 
quantitative morphology, Robert et al. demonstrated that OPCs are able to prevent 
collagenase-induced permeability increase in rat cerebral capillaries, aorta and cardiac 
muscle capillaries.128 In 2001, another publication described that OPCs counterbalance 
this deleterious effect of collagenase-evoked hyperpermeability in rat blood brain 
barrier by inhibiting proteolytic degradation of extracellular matrix macromolecules.129 
Furthermore, procyanidin130 as well as an enriched fraction of OPCs from grape 
seeds131 were found to block agonist-induced edema formation in rat hind paw. It was 
also shown in rats that OPCs partially prevent the formation of a re-expansion 
pulmonary edema probably due to their antioxidant activity.132 Moreover, Endotélon® 
(Sanofi Aventis, Paris, France), a French pharmaceutical product of OPCs from grape 
seeds, reduces surgically-evoked lymphedema in rat hindlimb.133 As a result, all these 
studies suggest a barrier protecting potential for oligomeric proanthocyanidins. The 
authors were not able to elucidate the distinct mechanisms of OPC-induced barrier 
protection. However, they speculate that binding of OPCs to areas with a high content 
of glycosaminoglycans134 might prevent degradation of extracellular matrix. This anti-
proteolytic property is believed to protect barrier function. 
Beyond this, we discovered that OPCs in WS® 1442 activate cAMP-signaling thereby 
protecting endothelial barrier. To our best knowledge, neither a detailed mode of 
action, nor a link between OPCs and the cAMP-signaling has ever been described to 
date.
 5 SUMMARY 
  
5  SUMMARY 77 
We demonstrated for the first time that WS® 1442 increases [Ca2+]i without impairing 
barrier integrity or cell viability. All important effects related to endothelial Ca2+-signaling 
are illustrated schematically in Figure 34. 
In brief, WS® 1442 
 depletes the ER by activating IP3 pathway and inhibiting SERCA.  
 does not cause SOCE despite increasing [Ca2+]i. 
 prevents agonist-induced SOCE generation. 
 blocks endothelial Ca2+ extrusion capacity. 
 does not target endothelial Na+/K+-ATPase (in contrast to cardiomyocytes). 
 
 
Figure 34  WS® 1442-induced Ca2+-signaling 
Focusing on the search for the bioactive compounds, only the flavonoid rich fraction 32 
and particular subfractions are able to alter thrombin-induced Ca2+-signaling. Similar to 
the original extract, the Ca2+-active fractions do not cause cellular stress. Although 
three inactive flavonoids of the extract could be identified in our lab, we hypothesize 
that certain flavonoids provide the key players of WS® 1442-induced Ca2+-signaling in 
agreement to the evidence found in literature. In the future, further fractionation 
procedures as well as structural analysis are needed to discover the Ca2+-active single 
compound(s) of WS® 1442. Concerning cAMP-signaling, only the OPC rich fraction 34 
as well as its subfractions 34.3 and 34.5 are found to activate this pathway most 
significantly. Additionally, the two isolated procyanidins B2 and C1 also induce 
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activation of the cAMP downstream effector cortactin. Therefore, we propose that 
OPCs in WS® 1442 are responsible for the activation of the cAMP pathway in the 
endothelium thereby protecting and strengthening endothelial barrier function.  
These findings strengthen the rational basis for the use of this herbal medicinal 
product by providing a better understanding of the complex pharmacological 
action of WS® 1442. 
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7.1 Abbreviations 
Table 17  Abbreviations 
Acronym Term 
AJ(s) Adherens junction(s) 
2-APB 2-Aminoethyldiphenyl borate 
BHQ 2,5-Di-tert-butylhydroquinone 
Blotto Non-fat dry milk powder  
BSA Bovine serum albumin 
cAMP Cylic adenosine monophosphate 
[Ca2+]ER Calcium concentration of the endoplasmic recticulum 
[Ca2+]i Intracellular calcium concentration 
CaM Calmodulin 
DAG Diacylglycerol 
DMEM Dulbecco’s modified Eagle’s medium 
EC(s) Endothelial cell(s) 
ECGM Endothelial cell growth medium 
EPAC1 Exchange protein directly activated by cAMP 1 
ER Endoplasmic reticulum 
FCPC Fast centrifugal partition chromatography 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FRET Fluorescence resonance energy transfer 
GEF(s) Guanine nucleotide exchange factor(s) 
GPCR G-protein coupled receptor 
HAT Hypoxanthin, aminopterin, thymidine 
HMEC Human dermal microvascular endothelial cells 
HUVECs Human umbilical vein endothelial cells 
H1 R Histamine receptor 1 
IEJ(s) Interendothelial junction(s) 
IP3 Inositol-1,4,5-trisphosphate 
MLC(K, P) Myosin light chain (kinase, phosphatase) 
NCX Na+/Ca2+-exchanger 
NYHA New York Heart Association 
OPCs Oligomeric proanthocyanidins 
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Acronym Term 
PAR1 Proteinase activated receptor 1 
PHPLC Preparative high performance liquid chromatography 
PKA Protein kinase A 
PKCα Protein kinase C α 
PLCβ Phospholipase C β 
PMCA Plasma membrane calcium ATPase 
PMSF Phenylmethylsulfonyl fluoride 
SDS Sodium dodecyl sulfate 
SERCA Sarcoplasmic/endoplasmic reticulum calcium ATPase 
skMLCK Skeletal muscle myosin light chain kinase 
SOC(E) Store-operated calcium (entry) 
Stim-1 Stromal interaction molecule-1 
S1-P Sphingosine 1-phosphate 
T/E Trypsin/EDTA 
TRPC channel Canonical transient receptor potential channel 
VASP Vasodilator-stimulated phosphoprotein 
VE-cadherin Vascular endothelial cadherin 
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